| Entries |
| Document | Title | Date |
|---|
| 20080200649 | Method - A method for optimised refolding of a protein which method comprises selecting for the protein at least three control factors which affect refolding of the protein and at least three levels for each control factor, making a Taguchi matrix of the control factors and levels, conducting experiments as required by the matrix, and refolding the protein in a process using the control factors at levels determined by the outcomes of the matrix experiments. | 08-21-2008 |
| 20080200650 | Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use - The present invention provides isolated polypeptides isolatable from a | 08-21-2008 |
| 20080207877 | Modified Human Four Helical Bundle Polypeptides and Their Uses - Modified human four helical bundle (4HB) polypeptides and uses thereof are provided. | 08-28-2008 |
| 20080214784 | HUMAN T1R2 TASTE RECEPTOR POLYPEPTIDES - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular taste stimulus in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed. | 09-04-2008 |
| 20080221305 | Polynucleotides encoding novel adiponectin receptor variants - The present invention provides novel polynucleotides encoding human AdipoR2v1 polypeptides, mouse AdipoR2v1 polypeptides, human AdipoR3 polypeptides, human AdipoR2v2 polypeptides, human AdipoR3v1 polypeptides, rat AdipoR1 polypeptides, rat AdipoR2 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human AdipoR2v1 polypeptides, mouse AdipoR2v1 polypeptides, human AdipoR3 polypeptides, human AdipoR2v2 polypeptides, human AdipoR3v1 polypeptides, rat AdipoR1 polypeptides, rat AdipoR2 polypeptides, to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention. | 09-11-2008 |
| 20080227956 | Novel morphogenic protein compositions of matter - Disclosed are novel compositions of morphogenic proteins constituting soluble forms of these proteins, antibodies that distinguish between soluble and mature forms, and method for producing these morphogenic proteins and antibodies. | 09-18-2008 |
| 20080234468 | Novel 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor - The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 gene has been introduced or disrupted. The invention still further provides isolated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 proteins, fusion proteins, antigenic peptides and anti-27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 09-25-2008 |
| 20080242839 | HUMAN CYTOKINE RECEPTOR - Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.” | 10-02-2008 |
| 20080242840 | NOVEL INHIBITORS OF ANGIOGENESIS AND TUMOR GROWTH - This invention provides for polypeptides that have surprising anti-angiogenic activity. These peptides are derived from Saposin B, a previously known protein involved in the hydrolysis of sphingolipids. In addition, methods of treating mammals with these anti-angiogenic polypeptides are provided, as well as the pharmaceutical compositions used to treat. Furthermore, the polypeptides of this invention can be used in fusion proteins, wherein the fusion proteins also comprise cell targeting or cytotoxic moieties. Also provided is the receptor to which these polypeptides bind. | 10-02-2008 |
| 20080242841 | METHODS OF MODULATING COLD SENSORY PERCEPTION - The present invention relates to regulation of cold sensation and pain. More particularly, the present invention is directed to nucleic acids encoding a member of the transient regulatory protein family, CMR1, which is involved in modulation of the perception of cold sensations and pain. The invention further relates to methods for identifying and using agents that modulate cold responses and pain responses stimulated by cold via modulation of CMR1 and CMR1-related signal transduction. | 10-02-2008 |
| 20080255339 | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities - The present invention relates to chimeric proteins with cell-targeting specificity and apoptosis-inducing activities. In particular, the invention is illustrated by examples of chimeric proteins including recombinant chimeric proteins between a gonadoptropin releasing hormone (GnRH) and an apoptosis-inducing moiety, such as a pro-apoptotic member of Bcl-2 family, such as Bik, Bax and Bak, or caspases, such as caspase-3. The chimeric proteins specifically target cells expressing a GnRH-binding site, such as adenocarcinoma cells, and induce cell-specific apoptosis. | 10-16-2008 |
| 20080255340 | ANGIOGENIN COMPLEXES (ANGex) AND USES THEREOF - Stabilized angiogenin compositions and methods of preparing a stabilized angiogenin compositions by non-covalent immobilization on a naturally occurring substrate, such as a protein, lipid, nucleic acid or nucleotide substrate, are disclosed. | 10-16-2008 |
| 20080262202 | NOVEL CANCER-ASSOCIATED GENES - The present invention is related to a DNA comprising a nucleotide sequence encoding a polypeptide represented by SEQ ID NO:1 or SEQ ID NO:2. The DNA according to the present invention is highly expressed in prostatic adenocarcinoma and ovarian carcinoma, and is a cancer-associated gene, so that it is possible to inhibit cancer by blocking the binding of the present protein to its ligand. Accordingly, the present antibody is used not only in the detection of the present protein, but also as an agent for the treatment or prevention of cancers such as prostatic adenocarcinoma and ovarian carcinoma. | 10-23-2008 |
| 20080275217 | Proteins Having Effects Of Controlling Cell Migration And Cell Death - The present invention relates to which have a role in controlling neuronal cell migration and cell death as well as to the DNA which encode those proteins. It is an object of the present invention to provide control of cell migration and/or cell death by providing a method for screening for promoters or inhibitors of proteins which affect the control of cell migration and/or cell death of neurons by interacting with an actin-binding protein, Filamin 1, through promoting the degradation of Filamin 1 or the DNA encoding Filamin 1. The cDNAs of S-FILIP, L-FILIP and h-FILIP cDNAs, which interact with Filamin 1, thereby negatively affecting cell migration and cell death by promoting the degradation of the Filamin 1, were isolated and the full nucleotide and amino acid sequences thereof were determined. | 11-06-2008 |
| 20080275218 | LY6H GENE - The invention provides a brain-specific gene useful in treating Alzheimer's disease, for instance, which comprises a nucleotide sequence cording for the amino acid sequence shown in SEQ ID NO:1 and fragments thereof; an expression vector comprising the gene; a host cell comprising the expression vector; an expression product of the gene; an antibody against the product; a therapeutic and prophylactic composition for neurodegenerative disease; and the like. | 11-06-2008 |
| 20080287656 | Device and Method For Cell Free Analytical and Preparative Protein Synthesis - A device is disclosed which contains one or more pores | 11-20-2008 |
| 20080300384 | T-bet compositions and methods of use thereof - Isolated nucleic acid molecules encoding T-bet, and isolated T-bet proteins, are provided. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a T-bet transgene. The invention further provides T-bet fusion proteins and anti-T-bet antibodies. Methods of using the T-bet compositions of the invention are also disclosed, including methods for detecting T-bet activity in a biological sample, methods of modulating T-bet activity in a cell, and methods for identifying agents that modulate the activity of T-bet. | 12-04-2008 |
| 20080306244 | Renta: an HIV immunogen and uses thereof - The present invention provides artificial fusion proteins (AFPs) designed to elicit an anti-HIV immune response, as well as nucleic acid molecules and expression vectors encoding those proteins. The AFPs of the invention may comprise domains from various HIV proteins, including Reverse Trancriptase (RT), Env (gp41), Nef and Tat proteins, as well as at least one HIV CTL epitope associated with long-term, non-progression to AIDS; these domains are biologically-inactivated for one or more of the normal activity of those proteins or are partial protein sequences (and similarly biologically-inactivated). RENTA is an AFP in which the HIV domains are from an HIV Clade A consensus sequence and contains additional domains, useful for example, in monitoring expression levels or laboratory animal immune responses. Such domains are optionally included in the AFPs. Other aspects of the invention may include compositions for and methods of inducing an anti-HIV immune response in a subject, preferably using a DNA prime-MVA boost strategy, and preferably to induce a cell-mediated immune response. | 12-11-2008 |
| 20080312412 | Chimeric immunogens - Multimeric hybrid genes encoding the corresponding chimeric protein comprise a gene sequence coding for an antigenic region of a protein from a first pathogen linked to a gene sequence coding for an antigenic region of a protein from a second pathogen. The pathogens particularly are parainfluenza virus (PIV) and respiratory syncytial virus (RSV). A single recombinant immunogen is capable of protecting infants and similar susceptible individuals against diseases caused by both PIV and RSV. | 12-18-2008 |
| 20080312413 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO EPHRIN SIGNALING WITH CUPREDOXINS - The present invention relates to compositions and methods of use of cupredoxins, and variants, derivatives and structural equivalents of cupredoxins that interfere with the ephrin signaling system in mammalian cells. Specifically, the invention relates to compositions and methods that use cupredoxins, such as azurin, rusticyanin and plastocyanin, and variants, derivatives and structural equivalents thereof to treat cancer in mammals. | 12-18-2008 |
| 20080319167 | Clostridial toxin derivatives able to modify peripheral sensory afferent functions - This invention describes a novel agent for the targeted control of a mammalian cell activity, in particular the agent is used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent according to the invention comprises three Domains B, T and E linked together in the following manner: Domain B-Domain T-Domain E where Domain B is the Binding Domain which binds the agent to a Binding Site on the cell which undergoes endocytosis to produce an endosome, Domain T is the Translocation Domain which translocates the agent (with or without the Binding Site) from within the endosome across the endosomal membrane into the cytosol of the cell, Domain E is the Effector Domain which inhibits the ability of the Recyclable Membrane Vesicles to transport the Integral Membrane Proteins to the surface of the cell. | 12-25-2008 |
| 20080319168 | Method for Coating Surfaces with Hydrophobins - A method for coating surfaces with hydrophobin fusions at a pH of ≧4, and a surface having a coating which comprises at least one hydrophobin fusion. | 12-25-2008 |
| 20080319169 | Biomimetic materials for protein storage and transport - The invention provides a method for the insertion of protein in storage vehicles and the recovery of the proteins from the vehicles, the method comprising supplying isolated protein; mixing the isolated protein with a fluid so as to form a mixture, the fluid comprising saturated phospholipids, lipopolymers, and a surfactant; cycling the mixture between a first temperature and a second temperature; maintaining the mixture as a solid for an indefinite period of time; diluting the mixture in detergent buffer so as to disrupt the composition of the mixture, and diluting to disrupt the fluid in its low viscosity state for removal of the guest molecules by, for example, dialysis, filtering or chromatography dialyzing/filtering the emulsified solid. | 12-25-2008 |
| 20090005537 | Process for constructing strain having compactin hydroxylation ability - The present invention is directed to methods and compositions for microbial based production of pravastatin. The compositions of the invention include novel strains of microorganisms that are capable of efficiently hydroxylating compactin (ML-236 B) resulting in production of pravastatin. In particular, the microorganisms of the invention are genetically engineered to express both cytochrome P-450 and the fdxshe or fdxshe-like protein. The invention further relates to the use of such microorganisms in processes designed for production of pravastatin for use in treatment of disease such as hypercholesterolemia and hyperlipidemia. | 01-01-2009 |
| 20090005538 | Apoptosis-Inducing Agent for Prostate Cancer Cells - According to the present invention, an apoptosis-inducing agent for prostate cancer comprising REIC/Dkk-3 DNA or an REIC/Dkk-3 protein, and a therapeutic agent for prostate cancer and an agent for inhibiting prostate cancer metastasis that comprise such apoptosis-inducing agent are provided. | 01-01-2009 |
| 20090012266 | Anti-TNFalpha Antibodies and Methods of Use - Novel TNFα antibody polypeptides and nucleic acids are disclosed. Methods of utilizing the polypeptides to treat TNFα-related diseases are also disclosed. | 01-08-2009 |
| 20090018312 | IGF-1 RECEPTOR INTERACTING PROTEINS - The invention comprises a nucleic acid molecule with the sequence SEQ ID NO:5 and the complementary sequence, and its use in diagnosis and therapy. This nucleic acid molecule (IIP-10) is a gene which encodes an IGF-1 receptor binding polypeptide. | 01-15-2009 |
| 20090030182 | ACTIVATABLE RECOMBINANT NEUROTOXINS - Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids. | 01-29-2009 |
| 20090048431 | MULTIVALENT CLOSTRIDIAL TOXINS - The present invention is directed to multivalent Clostridial toxin comprising more than one binding domain directed to a cell surface molecule of a target cell. Such modified toxins are useful as therapeutic compositions to prevent exocytosis and secretion by the target cell. Conditions in which such compositions man be useful include, without limitation, disorders of the sensory or motor nervous system, acute or chronic pain, cancer, pancreatitis, hyperhydrosis, glandular disorders, viral infections, cystic fibrosis and the like. The invention is also directed to methods of using and administering such a composition, and methods of treating a given condition using such a composition. | 02-19-2009 |
| 20090054624 | PRO1190 POLYPEPTIDES - The present invention is directed to novel polypeptides having homology to CDO protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention. | 02-26-2009 |
| 20090054625 | RECOMBINANT PROTEIN VARIANTS - The present invention relates to novel recombinant protein variants that are useful as immunotherapeutic components. Also the present invention relates to DNA sequences encoding said protein variants as well as compositions comprising said protein variants. | 02-26-2009 |
| 20090054626 | CRUSTACEAN-DERIVED PROTEIN HAVING ANTIFREEZE ACTIVITY - A crustacean-derived protein having antifreeze activity which under reduced conditions has a molecular weight, as measured by sodium dodecyl sulfate (SDS)—polyacrylamide gel electrophoresis, of about 37,000, about 16,000, and/or about 15,400; and the N-terminal amino acids are indicated by SEQ ID No. 1 or SEQ ID No. 2. | 02-26-2009 |
| 20090062513 | PRODUCTION OF BYPOLYMER FILM, FIBRE, FOAM AND ADHESIVE MATERIALS FROM SOLUBLE S-SULFONATED KERATIN DERIVATIVE - Film, fibre, foam and adhesive materials are produced from soluble S-sulfonated keratins. Once formed, the films, fibres, foams or adhesives are treated to modify the properties of the materials, in particular to improve the wet strength of the materials. Treatments used include removal of the S-sulfonate group by treatment with a reducing agent, treatment with an acid or treatment with a common protein crosslinking agent or treatment with a reduced form of keratin or keratin protein. The films are made by solvent casting a solution of S-sulfonated keratin proteins, the foam made by freeze-drying a solution of S-sulfonated keratin proteins and the fibres made by extruding a solution of a S-sulfonated keratin protein. | 03-05-2009 |
| 20090069539 | Androgen regulated prostate specific nucleic acids - The present invention provides novel androgen regulated nucleic acid molecules. Related polypeptides and diagnostic methods also are provided. | 03-12-2009 |
| 20090076245 | HIV-1 Subtype Isolate Regulatory/Accessory Genes, and Modification and Derivatives Thereof - The invention describes HIV-1 subtype isolate regulatory/accessory genes, and modifications and derivatives thereof. The genes which are described are the tat, nef and rev genes. Consensus amino acid sequences are also disclosed. The invention also relates to a vaccine including two or more of the nucleotide sequences, and nucleotide sequences from the pol and/or gag genes of HIV-1. | 03-19-2009 |
| 20090088556 | FUSION ANTIGEN USED AS VACCINE AND METHOD OF MAKING THEM - Fusion antigen used as vaccine and method of making them. The method includes: (1) selecting a segment of a virus protein sequence that contains a least one epitope; (2) engineering a DNA fragment encoding the selected segment of the virus protein; (3) inserting the DNA fragment into a | 04-02-2009 |
| 20090088557 | NOVEL SEMAPHORIN GENES (I) - The present invention provides a novel Semaphorin having neurite-outgrowth inhibition activity or proteins analogous thereto, peptide fragments of, or antibodies against, such proteins, genes encoding such proteins, expression vectors for said genes, transformed cells into which said expression vectors have been introduced, methods for producing a recombinant protein which employ said transformed cells, antisense nucleotides against the above genes, transgenic animals involving insertion or deletion of the above genes, and screening methods for antagonists of the above proteins, all of which are useful mainly in diagnoses, treatments, or studies relating to neurological diseases. The present invention further provides use of such proteins, peptides, antibodies, genes, or antisense nucleotides as pharmaceutical or diagnostic agents or laboratory reagents. | 04-02-2009 |
| 20090105453 | Interleukin-9 receptor mutants - This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma. | 04-23-2009 |
| 20090105454 | Prophylactic/therapeutic agent for cancer - A compound or its salt that regulates (preferably inhibits) the activity of a protein comprising the same or substantially the same amino acid sequence as represented by SEQ ID NO: 1, a compound or its salt that regulates (preferably inhibits) the expression of a gene for the protein, an antisense polynucleotide comprising the entire or part of a base sequence complementary or substantially complementary to a base sequence of a polynucleotide encoding the protein or its partial peptide, an antibody against the protein, etc. can be used as a prophylactic/therapeutic agent for cancer, etc., an apoptosis inducing agent, or the like. | 04-23-2009 |
| 20090124790 | CHROMATOGRAPHIC METHOD AND SYSTEM FOR PURIFYING A BOTULINUM TOXIN - Chromatographic processes and systems for purifying a botulinum toxin from an APF fermentation medium. | 05-14-2009 |
| 20090131637 | Vanilloid receptor - The isolated nucleic acid encoding human vanilloid receptor, said receptor, it's preparation, cells expressing said receptor and an assay for testing compounds for their potential to decrease pain in humans. The receptor is involved in detection of noxious stimuli in mammalian organisms. | 05-21-2009 |
| 20090149633 | ARTIFICIAL DIET FOR LEPIDOPTERAN INSECTS AND PRODUCTION METHOD THEREOF, LEPIDOPTERAN INSECT AND PRODUCTION METHOD THEREOF, AND BIOLOGICAL MATERIAL - An artificial diet for lepidopteran insects of the present invention, including: a protein; and a carbohydrate, wherein a content of a stable isotope is equal to or greater than 50 atom %. A method for producing an artificial diet for lepidopteran insects, including: a defatting treatment step of subjecting a microorganism to a defatting treatment; a hydrothermal solution extraction treatment step of subjecting the microorganism to an extraction treatment using a hydrothermal solution; and a mixing step of mixing a carbohydrate and a protein originated from the microorganism that is subjected to the defatting treatment step and the hydrothermal solution extraction treatment step. | 06-11-2009 |
| 20090156786 | Mammalian Genes: Related Reagents and Methods - Purified genes encoding proteins from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided. | 06-18-2009 |
| 20090176969 | CLONING GENES FROM STREPTOMYCES CYANEOGRISEUS SUBSP. NONCYANOGENUS FOR BIOSYNTHESIS OF ANTIBIOTICS AND METHODS OF USE - The present invention relates to the complete biosynthetic pathway for the formation of the LL-F28249 compounds and, most importantly, the major component LL-F28249α. The purified and isolated nucleic acid molecule encoding the proteins of the biosynthetic pathway, which is isolated from a wild-type or mutant | 07-09-2009 |
| 20090182121 | Regulation of Human Transmembrane Serine Protease - Reagents that regulate human transmembrane serine protease activity and reagents that bind to human transmembrane serine protease gene products can be used to regulate extracellular matrix degradation. Such regulation is particularly useful for treating COPD, metastasis of malignant cells, tumor angiogenesis, inflammation, atherosclerosis, neurodegenerative diseases, and pathogenic infections. | 07-16-2009 |
| 20090182122 | NUCLEIC ACID SEQUENCES ENCODING TRANSCRIPTION FACTOR PROTEINS - Isolated polynucleotides and polypeptides encoded thereby are described, together with the use of those products for making transgenic plants. | 07-16-2009 |
| 20090182123 | Method of Preparing Botulinum Neurotoxin Type E Light Chain - The present invention provides a preparation of botulinum toxin light chain type A or E, wherein the preparation is both catalytically active and soluble. Preferably, the preparation consists essentially of amino acid residues 1 through 425 of the botulinum toxin light chain type A. A method of screening inhibitors is also provided, wherein the method comprises exposing a test inhibitor to the preparation of botulinum toxin light chain type A and evaluating the biological activity of the preparation. In another embodiment, a method of providing a catalytically active, soluble preparation of botulinum toxin light chain, type A is provided, wherein the method comprises obtaining an expression vector comprising a DNA sequence encoding amino acid residues 1-425 and expressing a polypeptide. | 07-16-2009 |
| 20090182124 | NOVEL TRANSCRIPTION FACTOR HAVING ZINC FINGER DOMAINS - Using an undifferentiated mouse CL6 cell line, DMSO was added to induce its differentiation into cardiac muscular cells in order to obtain gene fragments whose expression elevated upon the induction. The isolated gene had zinc finger domains and showed a significant homology to the Sp1 family genes. Furthermore, a human gene corresponding to this mouse gene was isolated. The protein encoded by this gene existed in the nucleus and bonded to a GC-box. The protein was revealed to repress the transcription regulatory activity of the CMV promoter and thus serves as a transcription factor. | 07-16-2009 |
| 20090187006 | NOVEL PROTEIN, A GENE ENCODING THEREFOR AND A METHOD OF USING THE SAME - An object of the present invention is to search and identify novel antifungal proteins capable of inhibiting the growth of plant pathogenic microorganisms including | 07-23-2009 |
| 20090192290 | New bacillus thuringiensis strains and their insecticidal proteins - Four novel | 07-30-2009 |
| 20090192291 | PRODUCTION OF HOMOTRIMERIC FUSION PROTEINS - The present invention provides method for producing trimeric tumor necrosis factor receptors that are potent inhibitors of their cognate ligands. More particularly, the present invention provides polypeptides that comprise: (1) an extracellular domain of the transmembrane activator and CAML (calcium-signal modulating cyclophilin ligand) interactor (TACI), and (2) a trimerizing polypeptide. Suitable TACI extracellular domains include: (1) amino acid residues 30 to 110 of SEQ ID NO:4, (2) amino acid residues 1 to 110 of SEQ ID NO:4, (3) amino acid residues 30 to 154 of SEQ ID NO:4, and (4) amino acid residues 1 to 154 of SEQ ID NO:4. Illustrative trimerizing polypeptides include a trimerizing fragment of Heat Shock Binding Protein-1. The present invention further provides homotrimeric complexes of fusion proteins comprising a TACI extracellular domain and a trimerizing polypeptide. | 07-30-2009 |
| 20090192292 | MURINE ZCYTOR17 LIGAND POLYPEPTIDES AND POLYNUCLEOTIDES - The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 07-30-2009 |
| 20090192293 | ANTIBODIES TO NON-FUNCTIONAL P2X7 RECEPTOR - The present invention provides antibodies that specifically bind to P2X | 07-30-2009 |
| 20090198042 | POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 08-06-2009 |
| 20090203882 | NOVEL MICROBIAL ENZYMES AND THEIR USE - Extracellular tyrosinases obtainable from | 08-13-2009 |
| 20090203883 | MUSSEL BIOADHESIVE - The present invention relates to a bioadhesive derived from mussel. In particular, it relates to a novel MGFP-3A MUTANT ( | 08-13-2009 |
| 20090203884 | CHIMERIC HIV FUSION PROTEINS AS VACCINES - A chimeric fusion protein useful as an immunogen for inducing HIV antigen-specific immune responses contains a first polypeptidyl region and a second polypeptidyl region. The first polypeptidyl region includes a Pseudomonas Exotoxin A (PE) binding domain and a PE translocation domain. The second polypeptidyl region includes (i) a first peptidyl segment containing a fragment of gp120 C1 domain, located at the N-terminus of the second peptidyl region; (ii) a second peptidyl segment containing a fragment of gp120 C5 domain, located at the C-terminus of the first peptidyl segment; and (iii) a third peptidyl segment containing a fragment of gp41, located at the C-terminus of the second peptidyl segment. The second polypeptidyl region contains an antigenic determinant specific to one subtype of HIV. An intermediate polypeptide containing a non-Env, HIV antigenic determinant selected from Gag24, Nef, Tat and Rev may be included. | 08-13-2009 |
| 20090203885 | Astrocyte Modulated Genes And Uses Thereof - The present invention relates to Astrocyte Modulated Genes (AMGs). AMGs are genes whose expression are modulated in human astrocytes grown in primary cell culture following the exposure of these cells to either the human immunodeficiency virus HIV-1 or to the HIV-1 protein gp120. AMGs comprise both Astrocyte Enhanced Genes (AEGs) and Astrocyte Suppressed Genes (ASGs). Thus, the present invention further relates to Astrocyte Enhanced Genes (AEGs), the expression of which are up-regulated in human astrocytes grown in primary cell culture that are exposed to either the human immunodeficiency virus HIV-1 or to the HIV-1 protein gp120, and to Astrocyte Suppressed Genes (ASGs), the expression of which are downregulated in human astrocytes grown in primary cell culture that are exposed to either the human immunodeficiency virus HIV-1 or to the HIV-1 protein gp120. Because they may play a role in HIV-associated dementia (“HAD”), AMGs may be used as markers in methods for screening for drugs that treat or prevent HAD. | 08-13-2009 |
| 20090209729 | Recombinant chemokine-antigen vaccine - A recombinant gene sequence that comprises human SLC gene, antigen gene, and IgG1-Fc fragment gene, wherein the SLC gene is linked upstream to the antigen gene, and the IgG1-Fc fragment is linked downstream to the antigen gene. This invention also relates to the application of the recombinant gene sequence in the preparation of gene vaccine. | 08-20-2009 |
| 20090209730 | METHOD FOR GENE TRANSFER INTO TARGET CELLS WITH RETROVIRUS - A polypeptide represented by SEQ. ID No. 13 and a gene encoding the polypeptide. | 08-20-2009 |
| 20090209731 | Heteromeric taste receptors - Heteromeric taste receptors are provided. These receptors comprise a first polypeptide containing extracellular domains and transmembrane domains wherein the extracellular domains are at least 95% identical to the extracellular domains of specific T1R1 polypeptides and the transmembrane domains are at least 95% identical to the corresponding transmembrane domains of the specific T1R1 polypeptide or a different GPCR; and a second polypeptide comprising extracellular and transmembrane domains wherein the extracellular domains are at least 95% identical to the extracellular domains of specific T1R3 polypeptides and the transmembrane domains are at least 95% identical to the corresponding transmembrane domains of the specific T1R3 polypeptide or a different GPCR. | 08-20-2009 |
| 20090215989 | Heterologous Protein Production Using The Twin Arginine Translocation Pathway - Provided are means for evaluating and identifying putative substrates of the twin arginine translocation (Tat) secretory pathway in | 08-27-2009 |
| 20090221794 | Human Protooncogene and Protein Encoded By Same - Disclosed are a novel protooncogene and a protein encoded by the same. The protooncogene of the present invention may be effectively used for diagnosing various cancers including breast cancer, leukemia, uterine cancer, malignant lymphoma, etc. | 09-03-2009 |
| 20090221795 | ACTIVE TRUNCATED FORM OF THE RNA POLYMERASE OF FLAVIVIRUS - The isolation and purification of two domains from a from a | 09-03-2009 |
| 20090221796 | Heteromeric taste receptors - Heteromeric taste receptors are provided. These receptors comprise a first polypeptide containing extracellular domains and transmembrane domains wherein the extracellular domains are at least 95% identical to the extracellular domains of specific T1R2 polypeptides and the transmembrane domains are at least 95% identical to the corresponding transmembrane domains of the specific T1R2 polypeptide or a different GPCR; and a second polypeptide comprising extracellular and transmembrane domains wherein the extracellular domains are at least 95% identical to the extracellular domains of specific T1R3 polypeptides and the transmembrane domains are at least 95% identical to the corresponding transmembrane domains of the specific T1R3 polypeptide or a different GPCR. | 09-03-2009 |
| 20090221797 | HETEROMERIC TASTE RECEPTORS - Heteromeric taste receptors are provided. These receptors comprise a first polypeptide which comprises extracellular and transmembrane domains wherein the transmembrane domains are at least 95% identical to the transmembrane domains of specific T1R1 polypeptides, and the extracellular domains are at least 95% identical to the corresponding extracellular domains of the specific T1R1 polypeptide or a different GPCR; and a second polypeptide which comprises extracellular and transmembrane domains wherein the transmembrane domains are at least 95% identical to the transmembrane domains of specific T1R3 polypeptides, and the extracellular domains are at least 95% identical to the corresponding extracellular domains of the specific T1R3 polypeptide or that of a different GPCR. | 09-03-2009 |
| 20090221798 | HETEROMERIC TASTE RECEPTORS - Heteromeric taste receptors are provided. These receptors comprise a first polypeptide which comprises extracellular and transmembrane domains wherein the transmembrane domains are at least 95% identical to the transmembrane domains of specific T1R2 polypeptides, and the extracellular domains are at least 95% identical to the corresponding extracellular domains of the specific T1R2 polypeptide or a different GPCR; and a second polypeptide which comprises extracellular and transmembrane domains wherein the transmembrane domains are at least 95% identical to the transmembrane domains of specific T1R3 polypeptides, and the extracellular domains are at least 95% identical to the corresponding extracellular domains of the specific T1R3 polypeptide or that of a different GPCR. | 09-03-2009 |
| 20090221799 | Novel Fluorescent and Colored Proteins, and Polynucleotides That Encode These Proteins - The subject invention provides new fluorescent and/or colored proteins, and polynucleotide sequences that encode these proteins. The subject invention further provides materials and methods useful for expressing these detectable proteins in biological systems. | 09-03-2009 |
| 20090234100 | OSTEOGENIC COMPOSITIONS COMPRISING AN AMIONO ACID SEQUENCE WHICH IS CAPABLE OF BEING PHOSPHORYLATED BY CAMK2 - Novel osteogenic compositions and methods are provided. In a broad aspect, the composition comprises either a first amino acid sequence which is capable of being phosphorylated by CAMK2; or a nucleic acid sequence encoding the first amino acid sequence; or a combination thereof. Optionally, the first amino acid sequence may further comprise a second amino acid sequence which is capable of binding the Smurf1 protein. Further, the composition may comprise a BMP protein and/or an agent capable of decreasing an amount or an activity of CAMK2. The compositions of the instant invention may be incorporated into an implant or delivered via a catheter. | 09-17-2009 |
| 20090234101 | DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS - In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein. | 09-17-2009 |
| 20090240035 | DNA REPLICATION PROTEINS OF GRAM POSITIVE BACTERIA AND THEIR USE TO SCREEN FOR CHEMICAL INHIBITORS - The present invention relates to alpha-large, alpha-small, delta, delta prime, tau, beta, SSB, DnaG, and DnaB encoding genes from Gram positive bacterium, preferably | 09-24-2009 |
| 20090247733 | Novel Bone Mineralization Proteins, DNA, Vectors, Expression Systems - The present invention is directed to isolated nucleic acid molecules that encode LIM mineralization protein, or LMP. The invention further provides vectors comprising nucleotide sequences that encode LMP, as well as host cells comprising those vectors. Moreover, the present invention relates to methods of inducing bone formation by transfecting osteogenic precursor cells with an isolated nucleic acid molecule comprising a nucleotide sequence encoding LIM mineralization protein. The transfection may occur ex vivo or in vivo by direct injection of virus or naked plasmid DNA. In a particular embodiment, the invention provides a method of fusing a spine by transfecting osteogenic precursor cells with an isolated nucleic acid molecule having a nucleotide sequence encoding LIM mineralization protein, admixing the transfected osteogenic precursor cells with a matrix and contacting the matrix with the spine. Finally, the invention relates to methods for inducing systemic bone formation by stable transfection of host cells with the vectors of the invention. | 10-01-2009 |
| 20090253898 | Mathematical Design of ION Channel Selectivity Via Inverse Problem Technology - Determining the structure of permanent charge for an ion channel formulates an abstract operator, describing ion channel parameters, comprising equations that are ill-posed. The model of ion channel behavior relates the function of the ion channel to the structure of permanent charge within the ion channel and concentrations ions around the ion channel under certain properties and boundary conditions. The model also includes regularization of the abstract operator by approximating the ill-posed equations with a family of well-posed equations. An estimate of the closeness of the well-posed solution to the ill-posed solution is provided. Providing stable and convergent algorithms allows the model to determine a stability for the regularized solution, so that a regularization parameter can determine a balance between the stability and accuracy of the solution. | 10-08-2009 |
| 20090259022 | CDNA ENCODING THE HUMAN ALPHA2 DELTA4 CALCIUM CHANNEL SUBUNIT - The present invention provides nucleic acid and polypeptide sequences describing an isoform of the α2δ-4 subunit of a voltage gated calcium channel. The nucleic acids described herein can be used to produce functional α2δ-4 protein. The calcium channel α2δ-4 protein may be isolated for the purposes of binding experiments or may be used in cells to form a functional calcium channel complex. | 10-15-2009 |
| 20090259023 | LIQUID BUFFERED GDF-5 FORMULATIONS - Improved formulations and methods are provided for stabilizing a solution of bone morphogenetic protein. The compositions comprise an acetate buffered solution of GDF-5 and other excipients wherein the solution has a pH of from about 4.2 to about 5.3, thereby providing for a biologically isotonic solution having improved stability of the GDF-5 protein during storage, handling, and use. | 10-15-2009 |
| 20090259024 | GLUCOSE DEHYDROGENASE FROM ASPERGILLUS ORYZAE - The present invention effectively produces glucose dehydrogenase derived from | 10-15-2009 |
| 20090259025 | Lactoferrin - A pure lactoferrin polypeptide containing no more than two metal ions per molecule, or a mixture of the polypeptide and a fragment thereof. The polypeptide or the mixture stimulates skeletal growth and inhibits bone resorption. Also disclosed is a method of treating a bone-related disorder with the polypeptide or the mixture. | 10-15-2009 |
| 20090264622 | Rhesus monkey Nur77 | 10-22-2009 |
| 20090264623 | SODIUM CHANNEL PROTEIN TYPE III ALPHA-SUBUNIT SPLICE VARIANT - The present invention is directed to a splice variant of a human sodium channel alpha subunit and methods and compositions for making and using the same. | 10-22-2009 |
| 20090264624 | HUMAN CYTOKINE RECEPTOR - Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.” | 10-22-2009 |
| 20090270591 | NOVEL SURFACE ANTIGEN - The invention provides a novel surface polypeptide from | 10-29-2009 |
| 20090270592 | Purified TNFR preparations - Purified protein preparations comprising tumor necrosis factor are disclosed. | 10-29-2009 |
| 20090270593 | NUCLEIC ACID BINDING SUBSTANCE CONTAINING CATALYTIC NUCLEATION NANOPARTICLES - A nucleic acid binding substance having an affinity for nucleic acid polymers. The nucleic acid binding substance is comprised of a nucleic acid binding element capable of specific binding to nucleic acid molecules and connected to a catalytic nucleation particle | 10-29-2009 |
| 20090270594 | USE OF THYMOSIN ALPHA 1 FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ALLERGIES - The invention concerns the use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies | 10-29-2009 |
| 20090286956 | DELTA3, FTHMA-070, TANGO85, TANGO77, SPOIL, NEOKINE, TANGO129, and INTEGRIN ALPHA SUBUNIT Protein and nucleic acid molecules and uses thereof - The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 11-19-2009 |
| 20090286957 | NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS OF USE THEREOF FOR DIAGNOSIS OF BREAST CANCER - Novel markers for breast cancer that are both sensitive and accurate. These markers are overexpressed in breast cancer specifically, as opposed to normal breast tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of breast cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between breast cancer and non-cancerous states. | 11-19-2009 |
| 20090306344 | METHOD OF REDUCING THE VISCOSITY OF MUCUS - Disclosed is a pO157 plasmid-specified polypeptide found in | 12-10-2009 |
| 20090326200 | Altered ospa of borrelia burgdorferi - Provided herein are OspA polypeptides from Lyme Disease-causing | 12-31-2009 |
| 20100010195 | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same - The present invention is directed to novel polypeptides having homology to members of the tumor necrosis factor receptor family and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. | 01-14-2010 |
| 20100010196 | COMPOSITIONS AND METHODS FOR NON-TARGETED ACTIVATION OF ENDOGENOUS GENES - The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more amplifiable markers located on the integrated vector. In another embodiment, the invention is directed to activation of endogenous genes by nontargeted integration of specialized activation vectors, which are provided by the invention, into the genome of a host cell. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. The invention also provides methods for isolation of nucleic acid molecules (particularly cDNA molecules) encoding a variety of proteins, including transmembrane proteins, and for isolation of cells expressing such transmembrane proteins which may be heterologous transmembrane proteins. The invention also is directed to isolated genes, gene products, nucleic acid molecules, to compositions comprising such genes, gene products and nucleic acid molecules, and to vectors and host cells comprising such genes and nucleic acid molecules, that may be used in a variety of therapeutic and diagnostic applications. Thus, by the present invention, endogenous genes, including those associated with human disease and development, may be activated and isolated without prior knowledge of the sequence, structure, function, or expression profile of the genes. | 01-14-2010 |
| 20100016552 | Novel hemopoietic receptor protein, NR10 - The inventors succeeded in isolating a novel hemopoietin receptor gene (NR10) using a sequence predicted from the extracted motif conserved in the amino acid sequences of known hemopoietin receptors. It was expected that two forms of NR10 exists, a transmembrane type and soluble form. Expression of the former type was detected in tissues containing hematopoietic cells. Thus, NR10 is a novel hemopoietin receptor molecule implicated in the regulation of the immune system and hematopoiesis in vivo. These novel receptors are useful in screening for novel hematopoietic factors capable of functionally binding to the receptor, or developing medicines to treat diseases related with the immune system or hematopoietic system. | 01-21-2010 |
| 20100016553 | Internalization - A target internalized within a cell (and a binding member that specifically binds thereto) can be identified in an efficient manner by segregating (or substantially segregating) genetic material encoding the binding member from genetic material encoding a binding member that binds to a target that is not internalized. This can be achieved by employing a display library of binding members having a genotype/phenotype linkage via a non-fusion protein format, whereby genetic material encoding non-in-ternalized targets can be segregated (or substantially segregated) without lysing the cells. Internalized genetic material subsequently can be isolated and amplified. | 01-21-2010 |
| 20100022751 | RECOMBINANT TOXIN FRAGMENTS - A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays. | 01-28-2010 |
| 20100022752 | IDENTIFYING COMPONENTS OF A NETWORK HAVING HIGH IMPORTANCE FOR NETWORK INTEGRITY - A computer system ( | 01-28-2010 |
| 20100036094 | Polypeptide Markers for the Diagnosis of Alzheimer's Disease - A method for the diagnosis of Alzheimer's disease, comprising the step of determining the presence or absence of at least one polypeptide marker in a sample, wherein the polypeptide marker is selected from markers 1 to 50 (frequency markers), or determining the amplitude of at least one polypeptide marker selected from markers 51 to 279 (amplitude markers) | 02-11-2010 |
| 20100036095 | Human CD59 mutants with modulated complement binding activity - Disclosed are compositions and methods using mutant CD59. Also disclosed is new insight into the CD59-C8/C9 binding interface and engineered soluble CD59 molecules with significantly improved complement inhibitory activity. | 02-11-2010 |
| 20100036096 | COMPOSITIONS AND METHODS FOR PRODUCING RECOMBINANT PROTEINS - A class of integral membrane proteins, referred to as Mistic polypeptides, their variants, fusion proteins including a Mistic polypeptide domain, and nucleic acid molecules encoding Mistic polypeptides and Mistic fusion proteins are disclosed herein. Also described are methods of using Mistic polypeptides and Mistic fusion proteins to produce and/or isolate recombinant proteins (including without limitation classes of eukaryotic proteins that have previously been intractable to recombinant bacterial expression, such as, eukaryotic integral membrane proteins). | 02-11-2010 |
| 20100041870 | LYOPHILIZATION ABOVE COLLAPSE - The present invention provides methods of lyophilizing a pharmaceutical substance involving a primary drying step executed at a product temperature at or above the collapse temperature. The invention also provides pharmaceutical substances lyophilized at or above the collapse temperature. | 02-18-2010 |
| 20100048868 | Polypeptides Having Binding Affinity for Her2 - A polypeptide is provided, which has a binding affinity for HER2 and which is related to a domain of staphylococcal protein A (SPA) in that the sequence of the polypeptide corresponds to the sequence of the SPA domain having from 1 to about 20 substitution mutations. Nucleic acid encoding the polypeptide, as well as expression vector and host cell for expressing the nucleic acid, are also provided. Also provided is the use of such a polypeptide as a medicament, and as a targeting agent for directing substances conjugated thereto to cells overexpressing HER2. Methods, and kits for performing the methods, are also provided, which methods and kits rely on the binding of the polypeptide to HER2. | 02-25-2010 |
| 20100048869 | AGENT COMPRISING G-CSF FOR PREVENTION AND TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY - Disclosed is an agent for preventing and treating diabetic peripheral neuropathy including a granulocyte colony stimulating factor (G-CSF) as an active ingredient, which is able to improve nerve conduction velocity and pain sensitivity by regenerating blood vessels in peripheral tissues and rehabilitating damaged nerve tissues. | 02-25-2010 |
| 20100048870 | IDENTIFYING COMPONENTS OF A NETWORK HAVING HIGH IMPORTANCE FOR NETWORK INTEGRITY - A computer system ( | 02-25-2010 |
| 20100048871 | Biosynthetic Polypeptides Utilizing Non-Naturally Encoded Amino Acids - Modified biosynthetic polypeptide molecules, methods for manufacturing, and uses thereof are provided. | 02-25-2010 |
| 20100069610 | SUBSTRATES USEFUL FOR FRET PROTEASE ASSAYS FOR BOTULINUM SEROTYPE A/E TXOINS - The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor. | 03-18-2010 |
| 20100069611 | CYTOLETHAL DISTENDING TOXINS AND DETECTION OF CAMPYLOBACTER BACTERIA USING THE SAME AS A TARGET - The present inventors succeeded in cloning the CDT genes of | 03-18-2010 |
| 20100087624 | Methods for making recombinant proteins using apoptosis inhibitors - The invention provided improved methods of making and producing recombinant proteins in in vitro cultures of host cells using apoptosis inhibitors. The use of one or more apoptosis inhibitors in the methods can reduce apoptosis in the cell cultures and markedly improve yield of the desired recombinant proteins. | 04-08-2010 |
| 20100087625 | METHOD OF ENHANCING RECOMBINANT PROTEIN PRODUCTION - The present invention provides a method of enhanced protein production that comprises the step of expressing a recombinant gene encoding the protein in eukaryotic cells under conditions in which cleavage of the pro-domain of the protein is inhibited or eliminated. Generally the method of the present invention includes the step of inhibiting or altering the cleavage of a pro-domain of a recombinant protein of interest in order to increase the amount of recombinant protein secreted from a eukaryotic cell. Recombinant proteins that can be prepared using the method of this invention include members of the transforming growth factor-β (TGF-β) superfamily, such as bone morphogenetic proteins. Also provided are genetically engineered cells and polynucleotides for performing the method of the invention. | 04-08-2010 |
| 20100099848 | RANKL PRODUCTION INHIBITOR - The production of RANKL may be inhibited by orally ingesting a milk-derived basic protein. Thus, a RANKL production inhibitor containing a milk-derived basic protein fraction as an active ingredient; a therapeutic agent for a metabolic bone disease and a therapeutic agent for an immune disease each containing the RANKL production inhibitor; and a food/beverage and a feed each containing a specified amount of the RANKL production inhibitor and being characterized by inhibiting the production of RANKL have a remarkable effect of inhibiting the production of RANKL, can be ingested on a daily basis, and exhibit high safety even when being ingested over a long period. | 04-22-2010 |
| 20100099849 | INTERLEUKIN-17 RECEPTOR HOMOLOGUE - Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor14.” | 04-22-2010 |
| 20100105865 | Nucleic acids and proteins from streptococcus groups a & b - The invention provides proteins from group B | 04-29-2010 |
| 20100105866 | MICROFLUIDIC MANIPULATION OF FLUIDS AND REACTIONS - The present invention relates generally to microfluidic structures, and more specifically, to microfluidic structures and methods including microreactors for manipulating fluids and reactions. In some embodiments, structures and methods for manipulating many (e.g., 1000) fluid samples, i.e., in the form of droplets, are described. Processes such as diffusion, evaporation, dilution, and precipitation can be controlled in each fluid sample. These methods also enable conditions within the fluid samples (e.g., concentration) to be controlled. Manipulation of fluid samples can be useful for a variety of applications, including testing for reaction conditions, e.g., in crystallization, chemical, and biological assays. | 04-29-2010 |
| 20100105867 | PROCESS FOR PRODUCING OSTEOCALCIN-CONTAINING EXTRACT - A process for producing an extract containing activated osteocalcin; an extract which can be obtained by this production process; a food, a drink, a drug, an oral cavity-care composition and a feed containing this extract; and a growth enhancer containing osteocalcin originating in a bone. | 04-29-2010 |
| 20100105868 | METHOD FOR DETECTING NEUROBLASTOMA - The present invention is intended to provide a means for judging the malignancy of neuroblastoma and the progress of spontaneous regression thereof. The present invention provides a method for detecting cancer which comprises detecting activation or inactivation of the lysosomal-associated protein multispanning transmembrane 5 (LAPTM5) gene and amplification of the MYCN gene in a specimens to evaluate the malignancy of the specimens and the progress of spontaneous regression. | 04-29-2010 |
| 20100113742 | Modified polypeptides stabilized in a desired conformation and methods for producing same - The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. | 05-06-2010 |
| 20100121030 | ANTAGONISM OR EVASION OF SOLUBLE CYTOKINE RECEPTORS - Herein is described a system to combat poxvirus infection wherein antagonists are developed that bind the soluble cytokine receptor but have no significant biological activity in the host, effectively blocking the virus-mediated suppressor of interferon function, thereby permitting the host's own cytokines to stimulate an antiviral response. Alternatively, interferon molecules can be developed that retain biological activity on their native receptors but fail to bind the viral cytokine binding protein, thereby circumventing this virus immune modulation mechanism. | 05-13-2010 |
| 20100121031 | MEMBRANE-PERMEANT PEPTIDE COMPLEXES FOR TREATMENT OF SEPSIS - Methods and compositions for treating sepsis and diseases and conditions involving cellular apoptosis using cell membrane-permeant peptide conjugates of a cell membrane permeant peptide together with anti-apoptotic domains of the TCL1 protein are provided. | 05-13-2010 |
| 20100125129 | Thermostable Fusion Proteins and Thermostable Adjuvant - Fusion proteins including maltodextrin-binding protein (MBP) domains that are thermally stable and soluble are provided. Methods for forming and using the fusion proteins are also provided. | 05-20-2010 |
| 20100130724 | MAMMALIAN CYTOKINES; RELATED REAGENTS AND METHODS - Purified genes encoding cytokines from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided. | 05-27-2010 |
| 20100130725 | METHODS FOR CHARACTERIZING MOLECULES - Drug discovery is a complex undertaking facing many challenges, not the least of which is a high attrition rate as many promising candidates prove ineffective or toxic in the clinic owing to a poor understanding of the diseases, and thus the biological systems, they target. Therefore, it is broadly agreed that to increase the productivity of drug discovery one needs a far deeper understanding of the molecular mechanisms of diseases, taking into account the full biological context of the drug target and moving beyond individual genes and proteins. The present methods rely on the use of label-free cellular assays, particularly the DMR index, to systematically display the mode of actions, the toxicity, and the target(s) and pathway(s) of any molecules. | 05-27-2010 |
| 20100137562 | MAVS IN THE PREVENTION AND TREATMENT OF VIRAL DISEASE - The present invention includes compositions and methods for the identification, characterization and use of a novel anti-viral protein that includes a mitochondrial anti-viral signaling protein. | 06-03-2010 |
| 20100137563 | Cysteine Protease Autoprocessing of Fusion Proteins - Disclosed are fusion proteins, polynucleotides that encode the disclosed fusion proteins, and methods for expressing and autoprocessing of the disclosed fusion proteins to obtain a target protein. The disclosed fusion proteins include an autoproteolytic cysteine protease fused to a heterologous polypeptide, which may be isolated as the target protein. Preferably, the protease activity of the cysteine protease is inducible. Suitable autoproteolytic cysteine proteases for the fusion proteins include the cysteine protease of the | 06-03-2010 |
| 20100145015 | COMPOSITIONS AND METHODS FOR INCREASING IMMUNOGENICITY OF GLYCOPROTEIN VACCINES - The present invention relates to the microbial immunogens engineered to bear α-gal epitope(s) for induction of potent humoral and cellular immune responses when administered to subjects having anti-Gal antibodies. In one embodiment, the present invention provides compositions and methods for propagating influenza virus in human, ape, Old World monkey or bird cells that have been engineered to express an α1,3galactosyltransferase (α 1,3GT) gene to produce virions bearing hemagglutinin molecules containing α-gal epitopes, to increase the immunogenicity of the influenza virus. In another embodiment, the present invention provides fusion proteins between influenza virus hemagglutinin and a microbial peptide or protein of interest, and enzymatic processing of this fusion protein to carry α-gal epitopes, to increase the immunogenicity of the microbial peptide or protein of interest. | 06-10-2010 |
| 20100145016 | COMPOSITIONS AND METHODS FOR PURIFYING CALRETICULIN - The present invention relates to compositions, methods for expressing, and related methods for purifying calreticulin that is free of an affinity label or tag (i.e., non-tagged calreticulin). The invention provides useful methods for commercial production of human calreticulin in a bacterial expression system such as | 06-10-2010 |
| 20100152422 | Compostion for Preventing and Treating Acetaminophen Inducing Liver Injury Comprising the Protein Extract from Porphyra Yezoensis - The present invention relates to a composition for preventing and treating acetaminophen induced liver injury comprising the protein extracts from | 06-17-2010 |
| 20100160607 | p16 MEDIATED REGULATION OF NMDA RECEPTORS - Discovered is a novel protein and variants thereof whose activity at the NMDA receptor causes an increased efflux of calcium ions through the channel of said receptor. This activity is downregulated by the NR3A subunit of NMDA. Also discovered are the nucleic acid sequences encoding said novel protein and variants thereof. The discovery is useful for the diagnosing of NMDA receptor dysregulation and the treatment of NMDA receptor dysregulation related disorders. In addition, the discovery is useful for the further discovery of modulators affecting the activity of the novel protein and variants thereof at the NMDA receptor. | 06-24-2010 |
| 20100160608 | PROTEIN STABILIZER - An excellent protein stabilizer is provided, which has the following effects: (1) low probability with contamination of pathogens, (2) the effect of stabilization on photoproteins, and (3) minimization of loss of activity under lyophilizing conditions. A peptide from fish is used as the active ingredient for the protein stabilizer. | 06-24-2010 |
| 20100160609 | Chimera Botulinum Toxin Type E - The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xDxxxLL (SEQ ID NO: 111) at the C-terminus, wherein x is any amino acid. | 06-24-2010 |
| 20100168386 | FUSION PROTEIN CARRYING NEUROTROPHIN ACROSS THE BLOOD-BRAIN BARRIER, ENCODING GENE AND USES THEREOF - Provided are fusion proteins which comprise a first region having at least 75% homology with the amino acid sequence of neurotrophin, and a second region, located at the C-terminal of the first region, having at least 75% homology with the amino acid sequence of protein transduction domain (PTD). Also provided is encoding gene and usage thereof. The fusion protein can translocate through cell membrane or even the blood-brain barrier (BBB). The fusion protein can be used to treat various central nervous system degenerative diseases and peripheral neuropathy. | 07-01-2010 |
| 20100168387 | Chimeric CrylE Delta Endotoxin and Methods of Controlling Insects - The present invention relates to a chimeric δ endotoxin protein Cry 1E of SEQ ID No. 1 with extraordinarily high insecticidal property and a chimera gene of SEQ ID No. 2 encoding the said chimeric protein, and also a method of treating insect infested plants using said chimera protein. | 07-01-2010 |
| 20100168388 | STABILIZED P53 PEPTIDES AND USES THEREOF - Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2. | 07-01-2010 |
| 20100168389 | PROCESS FOR PRODUCING EXTRACT FOR CELL-FREE PROTEIN SYNTHESIS AND CELL EXTRACT PRODUCED THEREBY - It is intended to provide a process for producing an extract for cell-free protein synthesis whereby the productivity of a protein and the production efficiency can be improved. Cells are cultured under suppressed growth conditions. In the stationary phase of the culture, the cells are collected and then disrupted. The above-described cells are preferably bacterial cells, in particular, | 07-01-2010 |
| 20100168390 | MHC MULTIMERS, METHODS FOR THEIR GENERATION, LABELING AND USE - The present invention describes novel methods to generate MHC multimers and methods to improve existing and new MHC multimers. The invention also describes improved methods for the use of MHC multimers in analysis of T-cells in samples including diagnostic and prognostic methods. Furthermore the use of MHC multimers in therapy are described, e.g. anti-tumour and anti-virus therapy, including isolation of antigen specific T-cells capable of inactivation or elimination of undesirable targeT-cells or isolation of specific T-cells capable of regulation of other immune cells. | 07-01-2010 |
| 20100174049 | Reversed mammalian protein-protein interaction trap - The invention relates to a recombinant receptor, comprising a ligand-binding domain and a signaling domain that comprises a heterologous bait polypeptide, which receptor is inactivated by binding of a prey polypeptide to the heterologous bait peptide, either in presence or absence of a ligand binding to the ligand-binding domain. The receptor is activated by addition of a compound that disrupts the bait-prey interaction. The invention also relates to a method of screening compounds that disrupt compound-compound binding using the recombinant receptor. | 07-08-2010 |
| 20100184954 | MONOMERIC RED FLUORESCENT PROTEINS - Disclosed are sequences encoding monomeric variants of DsRed fluorescent proteins and methods of use. | 07-22-2010 |
| 20100204450 | Preparation Method for a Protein With New Function Through Simultaneous Incorporation of Functional Elements - Disclosed is a method for preparing a protein having a new function. The method comprises (A) a functional element-designing step of designing functional elements required for a new function desired to impart to an existing protein scaffold; (B) a functional element-inserting step of simultaneously inserting at least two gene fragments corresponding to the designed functional elements into a protein scaffold gene; and (C) a mutant screening and improving step of screening a mutant having a new function from a library of mutants inserted with the mutant genes, and improving and optimizing the function of the screened mutant using a directed evolution technique. The method for preparing can be widely used for the development of therapeutic proteins and the creation of industrial enzymes in the fields of bioengineering and biotechnology. | 08-12-2010 |
| 20100204451 | INSULINOTROPIC PEPTIDE DERIVATIVE WHEREIN ITS N-TERMINAL AMINO ACID IS MODIFIED - The present invention relates to an N-terminal amino acid-modified insulinotropic peptide having a high activity, and to a pharmaceutical composition comprising the same. The insulinotropic peptide derivatives according to the present invention exhibit therapeutic effects, which are not observed in native and other insulinotropic peptide analogs. Therefore, the insulinotropic peptide derivatives and the pharmaceutical composition comprising the same according to the present invention can be effectively provided for the treatment of the diseases. | 08-12-2010 |
| 20100210819 | Biosensors to measure InsP3 concentration in living cells - Phosphoinositides participate in many signaling cascades via phospholipase C stimulation, which hydrolyzes phosphatidylinositol bisphosphate, producing second messengers diacylglycerol and inositol 1,4,5-trisphosphate (InsP | 08-19-2010 |
| 20100210820 | PROTEIN REFOLDING COLUMN FILLER AND COLUMN - It is an object of the present invention to provide: a protein refolding column filler, which is effective for the refolding, namely, the activation of the function, of an inactive protein with an as yet unformed higher order structure produced in | 08-19-2010 |
| 20100222551 | Highly thermostable fluorescent proteins - Thermostable fluorescent proteins (TSFPs), methods for generating these and other stability-enhanced proteins, polynucleotides encoding such proteins, and assays and method for using the TSFPs and TSFP-encoding nucleic acid molecules are provided. The TSFPs of the invention show extremely enhanced levels of stability and thermotolerance. In one case, for example, a TSFP of the invention is so stable it can be heated to 99° C. for short periods of time without denaturing, and retains 85% of its fluorescence when heated to 80° C. for several minutes. The invention also provides a method for generating stability-enhanced variants of a protein, including but not limited to fluorescent proteins. | 09-02-2010 |
| 20100234568 | Identification of peptide tags for the production of insoluble peptides by sequence scanning - A method is provided to identify short peptide tags, referred to here as inclusion body tags (IBTs), useful for the generation of insoluble fusion peptides. A library of genetic constructs were prepared encoding fusion peptides comprising an inclusion body tag of 10-50 contiguous amino acids from a full-length insoluble protein operably linked to a peptide of interest. The library was designed to include a sufficient number of overlapping inclusion body tags to ensure that the entire length of the full-length insoluble protein was represented. Host cells transformed and expressing the genetic constructs were evaluated for inclusion body formation. | 09-16-2010 |
| 20100234569 | AQUEOUS PROCESSING OF OILSEED PRESS CAKE - The subject invention relates in part to novel steps in canola and other oil seed processing, including milling to achieve a significant particle size reduction, extraction of higher levels of protein from the starting material, the use of presscake as a starting material, and the production of a precipitated protein concentrates containing a nutritionally significant amount of oil. The subject invention also provides optimal pH ranges for extraction and recovery steps in these novel processes. The subject processes can be applied to, and offer similar advantages to, other oilseeds and vegetable matter, such as sunflower seeds and flax seeds. The subject invention also includes novel feed compositions. | 09-16-2010 |
| 20100240868 | Composition and Method for a Producing Stable Amyloid Beta Oligomers of High Molecular Weight - The invention relates to a method for the preparation of a stable, soluble amyloid beta (Aβ) oligomer and composition thereof for use as an antigen for the generation of antibodies for the treatment of Alzheimer's disease and other conditions related to abnormal amyloid beta aggregation. The method which uses a pH in excess of 7.0 and high concentrations of Aβ, optionally includes the use of divalent anions or a helix-inducing solvent to form the oligomers. The stable, soluble Aβ oligomers produced by the method herein have a particle size of 10 to 100 nm in diameter, when measured by a dynamic light scattering technique, and a molecular weight of 100 to 500 kDa. | 09-23-2010 |
| 20100240869 | GENE RELATED TO GROWTH PROMOTING FUNCTION OF ACETIC ACID BACTERIUM, ACETIC ACID BACTERIUM BRED USING THE GENE AND METHOD FOR PRODUCING VINEGAR USING THE ACETIC ACID BACTERIUM - The present invention is to obtain a novel gene that encodes a protein having a function of promoting acetic acid bacterial growth in the presence of a high concentration of acetic acid; to enhance acetic acid bacteria's function of promoting growth and thereby to develop acetic acid bacteria with an improved fermentation ability in the presence of a high concentration of acetic acid; and to provide a method for efficiently producing vinegar that contains a high concentration of acetic acid in a short time using the acetic acid bacterium. A novel gene having a function of improving the function of promoting growth at a practical level was cloned from acetic acid bacteria for practical use, belonging to the genus | 09-23-2010 |
| 20100249376 | NELL Peptide Expression Systems and Bone Formation Activity of NELL Peptide - The invention generally relates to a bone growth factor, and more particularly to compositions including NELL1, articles of manufacture including NELL1 and methods of using NELL1 to induce bone formation. This invention also provides methods for the expression and purification of NELL1 and NELL2 peptides. | 09-30-2010 |
| 20100249377 | ENGINEERED HYBIRD PHAGE VECTORS FOR THE DESIGN AND THE GENERATION OF A HUMAN NON-ANTIBODY PEPTIDE OR PROTEIN PHAGE LIBRARY VIA FUSION TO pIX OF M13 PHAGE - The invention relates to a compositions and methods for generating and using pIX phage display libraries for producing non-antibody peptide or protein proteins or peptides using engineered hybrid phage vectors derived from pIX of M 13 phage | 09-30-2010 |
| 20100261880 | LY6H POLYPEPTIDE - The invention provides a brain-specific gene useful in treating Alzheimer's disease, for instance, which comprises a nucleotide sequence cording for the amino acid sequence shown in SQ ID NO:1 and fragments thereof; an expression vector comprising the gene; a host cell comprising the expression vector; an expression product of the gene; an antibody against the product; a therapeutic and prophylactic composition for neurodegenerative disease; and the like. | 10-14-2010 |
| 20100261881 | MARKER SEQUENCES FOR RHEUMATOID ARTHRITIS AND USE THEREOF - The present invention relates to new marker sequences for rheumatoid arthritis and the diagnostic use thereof together with a method for screening of potential active substances for rheumatoid arthritis by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such marker sequences for rheumatoid arthritis, in particular a protein biochip and the use thereof. | 10-14-2010 |
| 20100261882 | METHOD AND APPARATUS FOR ASSESSING POLYPEPTIDE AGGREGATION - A method of determining aggregation rate data predicting an aggregation rate of a polypeptide defined by an amino acid sequence, the method comprising determining a hydrophobicity value, a charge value, and at least one shape propensity value for said sequence; identifying one or more aggregation-influencing patterns within said sequence; determining a pattern value for the sequence responsive to said identifying; and determining said aggregation rate data by determining a weighted combination of said hydrophobicity value, said charge value, said at least one shape propensity value, said pattern value and at least one factor extrinsic to said amino acid sequence. | 10-14-2010 |
| 20100261883 | BONE RESORPTION INHIBITORY FOOD MATERIAL FOR INHIBITING BONE RESORPTION - A milk protein fraction having following properties (1) to (4) is excellent in bone resorption inhibitory effect, and is useful for preventing or treating bone diseases:
| 10-14-2010 |
| 20100261884 | CLOSTRIDIUM PERFRINGENS ALPHA TOXIN PROTEINS - This invention pertains in part to the development of a vaccine for poultry against necrotic enteritis (NE). The vaccine utilizes a protective antigen that is a mutated, full-length, non-toxic | 10-14-2010 |
| 20100267929 | PRRS Viruses, Infectious Clones, Mutants Thereof, and Methods of Use - The present invention provides isolated infectious polynucleotides, such as infectious clones, having a nucleotide sequence with identity to PRRS viruses such as VR-2332, Lelystad, or others, and optionally further including a deletion in a region of ORF1 that encodes the nsp2 polypeptide. | 10-21-2010 |
| 20100267930 | SLO2 and SLO4, Novel Potassium Channel Proteins from Human Brain - The invention provides isolated nucleic acid and amino acid sequences of Slo2 and Slo4, members of the Slo family of potassium channel proteins, also known as “maxi” or BK potassium channel proteins. Also provided herein are antibodies to Slo2 and Slo 4, methods of detecting Slo2 and Slo 4, methods of screening for potassium channel activators and inhibitors using biologically active Slo2 and Slo 4, and kits for screening for activators and inhibitors of voltage-gated potassium channels comprising Slo2 and Slo 4. | 10-21-2010 |
| 20100267931 | HETEROLOGOUS EXPRESSION OF NEISSERIAL PROTEINS - Alternative and improved approaches to the heterologous expression of the proteins of | 10-21-2010 |
| 20100273985 | POST-TRANSLATIONAL MODIFICATIONS AND CLOSTRIDIAL NEUROTOXINS - The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain. | 10-28-2010 |
| 20100273986 | POST-TRANSLATIONAL MODIFICATION AND CLOSTRIDIAL NEUROTOXINS - The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain. | 10-28-2010 |
| 20100273987 | Soybean Cultivar 89146110 - A soybean cultivar designated 89146110 is disclosed. The invention relates to the seeds of soybean cultivar 89146110, to the plants of soybean 89146110, to plant parts of soybean cultivar 89146110 and to methods for producing a soybean plant produced by crossing soybean cultivar 89146110 with itself or with another soybean variety. The invention also relates to methods for producing a soybean plant containing in its genetic material one or more transgenes and to the transgenic soybean plants and plant parts produced by those methods. This invention also relates to soybean cultivars or breeding cultivars and plant parts derived from soybean variety 89146110, to methods for producing other soybean cultivars, lines or plant parts derived from soybean cultivar 89146110 and to the soybean plants, varieties, and their parts derived from use of those methods. The invention further relates to hybrid soybean seeds, plants and plant parts produced by crossing the cultivar 89146110 with another soybean cultivar. | 10-28-2010 |
| 20100280222 | CLOSTRIDIAL NEUROTOXIN COMPOSITIONS AND MODIFIED CLOSTRIDIAL NEUROTOXINS - Natural and modified neurotoxins and isolated neurotoxin compositions are described. The neurotoxins may include one or more structural modifications, wherein the structural modification(s) alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification(s). In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain. | 11-04-2010 |
| 20100280223 | METHOD FOR DETERMINING AND PREDICTING PROTEIN AUTONOMOUS FOLDING - Techniques for determining an equilibrium structure of a protein in a predetermined environment, the protein having Ramachandran angles and a known denatured structure, are disclosed. In a preferred embodiment, a method is presented which involves determining a maximum RMS volume of the known denatured structure of the protein and calculating at least one force on the protein in its current structure in the predetermined environment. The net torque resulting from the at least one force for each of the Ramachandran angles of the protein is then determined. Then at least one section of the protein structure on a side of a Ramachandran angle with greatest torque is rotated to form a new structure. A new RMS volume for the new structure is then calculated, and the method is repeated using the new structure. The method ceases when the new RMS volume of the new protein structure is not less than the RMS volume of the starting structure. | 11-04-2010 |
| 20100280224 | MARKER SEQUENCES FOR MULTIPLE SCLEROSIS AND USE THEREOF - The present invention relates to new marker sequences for multiple sclerosis and the diagnostic use thereof together with a method for screening of potential active substances for multiple sclerosis by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such marker sequences for multiple sclerosis, in particular a protein biochip and the use thereof. | 11-04-2010 |
| 20100280225 | FUNGUS-INDUCED INFLAMMATION AND EOSINOPHIL DEGRANULATION - This document relates to methods and materials involved in fungus-induced inflammation and eosinophil degranulation. For example, isolated nucleic acids encoding fungal polypeptides, fungal polypeptides, methods for assessing fungus-induced inflammation, methods for assessing eosinophil degranulation, and methods for identifying inhibitors of fungus-induced inflammation and/or eosinophil degranulation are provided. | 11-04-2010 |
| 20100286369 | METHODS FOR GENERATING POLYNUCLEOTIDES HAVING DESIRED CHARACTERISTICS BY ITERATIVE SELECTION AND RECOMBINATION - A method for DNA reassembly after random fragmentation, and its application to mutagenesis of nucleic acid sequences by in vitro or in vivo recombination is described. In particular, a method for the production of nucleic acid fragments or polynucleotides encoding mutant proteins is described. The present invention also relates to a method of repeated cycles of mutagenesis, shuffling and selection which allow for the directed molecular evolution in vitro or in vivo of proteins. | 11-11-2010 |
| 20100286370 | Novel fluorescent protein molecules - The present invention relates to novel fluorescent proteins and to methods of making these proteins and the uses thereof. | 11-11-2010 |
| 20100286371 | Methods of Activating Clostridial Toxins - The specification discloses modified Clostridial toxins comprising an exogenous Clostridial toxin di-chain loop protease cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins; method of producing such modified Clostridial toxins, method of activating such modified Clostridial toxins and methods of activating recombinantly-expressed Clostridial toxins. | 11-11-2010 |
| 20100286372 | Pregnane X Receptor Compositions, Crystals and Uses Thereof - The present invention relates, inter alia, to PXR polypeptides and crystals that are useful, for example, for crystallization and in assays for identification of modulators of PXR. | 11-11-2010 |
| 20100298539 | NOVEL POLYPEPTIDES AND USE THEREOF - The present invention provides a polypeptide having a biological activity of the Chemotaxis Inhibitory Protein of | 11-25-2010 |
| 20100298540 | Crystal Structure of a MarR Family Polypeptide - The crystal structure of the product, crystals of the MarR protein, a regulator of multiple antibiotic resistance in | 11-25-2010 |
| 20100298541 | Protein Scaffolds - The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds. | 11-25-2010 |
| 20100317833 | METHOD FOR THE PRODUCTION OF DRY FREE-FLOWING HYDROPHOBIN PREPARATIONS - Method for the production of dry, free-flowing, stable hydrophobin preparations by spraying and drying aqueous hydrophobin solutions, if appropriate comprising additives in a spray device. | 12-16-2010 |
| 20100324267 | NOVEL TRAF FAMILY PROTEINS - In accordance with the present invention, there are provided novel TRAF-Protein-Binding-Domain polypeptides (TPBDs). The invention also provides nucleic acid molecules encoding TPBDs, vectors containing these nucleic acid molecules and host cells containing the vectors. The invention also provides antibodies that can specifically bind to invention TPBDs. Such TPBDs and/or anti-TPBD antibodies are useful for discovery of drugs that suppress autoimmunity, inflammation, allergy, allograph rejection, sepsis, and other diseases. | 12-23-2010 |
| 20100331523 | Heterologous Protein Production Using The Twin Arginine Translocation Pathway - Provided are means for evaluating and identifying putative substrates of the twin arginine translocation (Tat) secretory pathway in | 12-30-2010 |
| 20110009597 | RECOMBINANT GANODERMA LUCIDIUM IMMUNOMODULATORY PROTEIN (rLZ-8) AND USES THEREOF - Provided are the use of the recombinant | 01-13-2011 |
| 20110021750 | Oral cancer biomarker and inspection method using the same - The present invention discloses an oral cancer biomarker and an inspection method using the same. The biomarker is Mca-2 binding protein (Mac-2BP), which can be directly detected in the specimen of the body fluid of a testee, and which can realize a fast and effective clinical diagnosis of oral cancer. | 01-27-2011 |
| 20110021751 | Plasmid Vector - To provide a plasmid vector having high productivity which can be used for large scale production of an industrially valuable and useful protein, and a transformant using the plasmid vector. A plasmid vector having DNA which encodes a plasmid replication protein in which one or more amino acid residues that are selected from (a) position 48, (b) position 262, (c) position 149 and (d) position 198 in the amino acid sequence represented by SEQ ID NO: 2 are substituted with (a) Ala, Gly, Thr, Arg, Glu, Asn or Gln, (b) Gly, Ser, Thr, Cys or Val, (c) Asn, and (d) Glu, respectively. | 01-27-2011 |
| 20110028688 | CRYSTAL STRUCTURE OF OX40L AND OX40L COMPLEXED WITH OX40 RECEPTOR - The present disclosure provides crystals of and structural coordinates of mOX40L, hOX40L, hOX40 receptor and complexes thereof. The crystals and crystal structures are useful, for example, in the design and synthesis of modulators of mOX40L, hOX40L, and/or hOX40 receptor. | 02-03-2011 |
| 20110028689 | NUCLEIC ACIDS THAT ENCODE SODIUM CHANNEL - A method or screen for assessing the potential of a compound to treat a pathological condition, such as arrhythmia, which is manifested by an increased late sodium current in a heart is disclosed. The method employs a mutant sodium channel protein having an amino acid sequence in which one or more amino acids among the ten amino acids occurring at the carboxy end of the S6 segments of D1, D2, D3 or D4 domains of mammalian Nav1 differs from the amino acid in wild-type Nav1 by substitution with tryptophan, phenylalanine, tyrosine or cysteine. Cells transfected with a nucleic acid that encodes a mutant mammalian Nav1 protein, as well as isolated nucleic acid comprising a nucleotide sequence that codes for a mutant mammalian Nav1 protein are disclosed. | 02-03-2011 |
| 20110028690 | NOVEL BAG PROTEINS AND NUCLEIC ACID MOLECULES ENCODING THEM - The present invention provides a family of BAG-1 related proteins from humans (BAG-1L, BAG-1, BAG-2, BAG-3, BAG-4 and BAG-5), the invertebrate | 02-03-2011 |
| 20110028691 | RECOMBINANT TOXIN FRAGMENTS - A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide, is possible and the polypeptide can be incorporated into vaccines and toxin assays. | 02-03-2011 |
| 20110034671 | Systems for Expression of Heterologous Proteins in M. Capsulatus - The present invention relates to an expression system for the expression of proteins and peptides in a methanotrophic bacterium, preferably | 02-10-2011 |
| 20110046350 | LENGTH-ADJUSTABLE NANOSCALE TETHER FOR BINDING TARGETS TO SUBSTRATES - Embodiments of the present invention are directed to reusable, length-adjustable nanoscale tethers that can be incorporated into a variety of different sensors and other electrical, electro-mechanical, electro-optical-mechanical, and optical-mechanical devices. An optionally reusable, length-adjustable nanoscale tether that represents one embodiment of the present invention comprises a binding-structure component, having a substrate-anchor subcomponent and a binding-adapter binding domain, and a binding adaptor that binds to the binding-adapter binding domain and that has a target-binding subcomponent that binds to a target molecule, target particle, or other target entity. The binding-adapter binding domain can be positioned at different distances from the substrate anchor within the binding-structure component so that the distance between a bound target and a sensor substrate can be precisely controlled. | 02-24-2011 |
| 20110046351 | MUTANT PROTEINS AND METHODS FOR SELECTING THEM - A method for selecting a membrane protein with increased stability, the method comprising: a) providing one or more mutants of a parent membrane protein in a membrane-containing composition, wherein the one or more mutants are exposed to an amount of a membrane destabilising agent which is effective to destabilise the parent membrane protein in-situ, b) determining whether the or each mutant membrane protein has increased stability with respect to its structure and/or a biological activity compared to the stability of the parent membrane protein with respect to its structure and/or the same biological activity, and c) selecting the one or more mutants which have increased stability compared to the stability of the parent membrane protein. | 02-24-2011 |
| 20110046352 | DISEASE-RESISTANT PLANTS AND METHOD OF CONSTRUCTING THE SAME - The present invention provides transgenic, disease-resistant plants which have been transformed with an expression cassette including a constitutive gene expression promoter; and a gene, under the control of the promoter, encoding a harpin. The transformed cells in the transgenic plant effect the constitutive expression of the harpin in an amount effective for inducing a defense reaction. The harpin is a protein consisting of an amino acid sequence that is at least 90% homologous to the amino acid sequence of SEQ ID NO: 2, and possesses a hypersensitive-response-inducing activity. The present invention also provides methods for producing the transgenic plants, expression cassettes, recombinant vectors and genes encoding harpins. | 02-24-2011 |
| 20110060126 | METHOD AND APPARATUS FOR OPTIMIZING CRYSTALLIZATION CONDITIONS OF A SUBSTRATE - The present invention relates to a multi-well crystallization plate comprising a plurality of wells, each well having therein a different crystallization media. Each crystallization media varying according to at least two different parameters. The first parameter has at least one condition, and the second parameter has at least two different conditions, whereby the multi-well plate allows facilitating optimization of crystallization conditions of a substrate. Methods for optimizing crystallization conditions of a substrate are also disclosed. | 03-10-2011 |
| 20110060127 | Structure Of Compstatin-C3 Complex And Use For Rational Drug Design - The structure of C3c in complex with the complement inhibitor, compstatin, and use of this information for rational design or identification of complement-inhibiting drugs are disclosed. | 03-10-2011 |
| 20110065898 | Immunosuppressant Target Proteins - The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes. | 03-17-2011 |
| 20110087006 | DNA Sequence Encoding a Retinoic Acid Regulated Protein - The present invention concerns a novel retinoic acid regulated gene whose expression product displays useful morphogenic/mitogenic properties. The present invention further concerns an isolated nucleic acid of SEQ ID NO:1 encoding a retinoic acid regulated expression product having an amino acid sequence of SEQ ID NO:2. | 04-14-2011 |
| 20110092674 | Non-Functional P2X7 Receptor - The present invention provides antibodies that specifically bind to P2X | 04-21-2011 |
| 20110098447 | Homogenous Populations of Molecules - The invention provides populations of molecules that are prepared as, or treated to become, homogeneous for one or more molecular characteristics. In an aspect, the invention relates to molecular weight standards that may be used to determine the molecular weight or apparent molecular weight of uncharacterized molecules, such as proteins and nucleic acids, as well as in other applications. In one aspect, the molecular weight standards are pre-stained. | 04-28-2011 |
| 20110124843 | METHOD FOR EFFICIENTLY AMPLIFYING ABNORMAL PRION PROTEIN DERIVED FROM BSE - A method for efficiently amplifying abnormal prion protein (PrP | 05-26-2011 |
| 20110130543 | CHOLESTEROL CONSENSUS MOTIF OF MEMBRANE PROTEINS - The invention provides the structure of a human β2-adrenergic receptor, a cholesterol consensus motif, and methods of identifying modulators of G-protein coupled receptors (GPCRs). Methods of using the modulators of the receptor, GPCRs, and the cholesterol consensus motif are also provided. | 06-02-2011 |
| 20110137012 | CELL CULTURE METHOD USING AMINO ACID-ENRICHED MEDIUM - Methods of culturing cells capable of producing desired proteins to obtain the proteins by use of a medium from which biological components are excluded as much as possible are provided. Specifically, a culture method characterized by culturing while maintaining a specific amino acid in a culture solution at a high concentration, and a cell culture fed-batch medium for use in the method are provided. | 06-09-2011 |
| 20110152500 | Bipodal-Peptide Binder - The present invention deals with a bipodal-peptide binder that specifically binds with a target including (a) a structure stabilizing region that includes parallel, antiparallel or parallel and antiparallel amino acid strands wherein interstrand non-covalent bonds are formed; and (b) a target binding region I and a target binding region II that are bonded at both terminals of said structure stabilizing region and respectively include n and m amino acids, and a method of preparing same; the bipodal-peptide binder of the present invention exhibits the KD value (dissociation constant) of a very low level (for example, nM level) and, therefore, exhibits very high affinity toward a target. The bipodal-peptide binder of the present invention has applications not only in pharmaceuticals but also in in-vivo imaging, in vitro cell imaging, and drug delivery targeting, and can be very usefully employed as an escort molecule. | 06-23-2011 |
| 20110152501 | Activatable Imaging Probes - The invention relates to activatable imaging probes that include a chromophore attachment moiety and a plurality of chromophores, such as near-infrared chromophores, chemically linked to the chromophore attachment moiety so that upon activation of the imaging probe by interaction with a target molecule the optical properties of the plurality of chromophores are altered. The probe optionally includes protective chains or chromophore spacers, or both. Also disclosed are methods of using the imaging probes for in vivo and in vitro optical imaging. | 06-23-2011 |
| 20110152502 | FLUORESCENT PROTEIN - The object of the present invention is to provide a novel fluorescent protein in which on and off of fluorescence thereof can be controlled by irradiation with lights of two different wavelengths. The present invention provides a fluorescent protein shown in the following (a) or (b); | 06-23-2011 |
| 20110160434 | FIBROMYALGIA TEST METHOD - A method for diagnosing or testing for fibromyalgia with a specific peptide in the blood as an indicator, as well as a method for effectively evaluating or assessing a fibromyalgia drug with the peptide as an indicator. A method for diagnosing or testing for fibromyalgia or for evaluating or assessing a fibromyalgia drug, by subjecting a patient's serum to peptide analysis using as an indicator (biomarker) a peptide that demonstrates a specific expression amount in the blood of a fibromyalgia patient. | 06-30-2011 |
| 20110166323 | CHIMERIC, HYBRID AND TANDEM POLYPEPTIDES OF MENINGOCOCCAL NMB1870 - NMB1870 is a protein in | 07-07-2011 |
| 20110166324 | IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS - The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided. | 07-07-2011 |
| 20110172393 | NOVEL FORMULATIONS WHICH STABILIZE AND INHIBIT PRECIPITATION OF IMMUNOGENIC COMPOSITIONS - The present invention addresses an ongoing need in the art to improve the stability of immunogenic compositions such as polysaccharide-protein conjugates and protein immunogens. The invention broadly relates to novel formulations which stabilize and inhibit precipitation of immunogenic compositions. More particularly, the invention described hereinafter, addresses a need in the art for formulations which stabilize and inhibit particulate formation (e.g., aggregation, precipitation) of immunogenic compositions which are processed, developed, formulated, manufactured and/or stored in container means such as fermentors, bioreactors, vials, flasks, bags, syringes, rubber stoppers, tubing and the like. | 07-14-2011 |
| 20110178271 | STERILIZATION METHOD - The present invention relates to a method for sterilization of different materials, especially sensitive material, such as chromatographic media with sensitive ligands. The method for sterilization of a chromatographic separation medium comprises exposing the separation medium to pressurized steam at a temperature of between about 121° C. and about 135° C. | 07-21-2011 |
| 20110178272 | ISOLATED BITTER TASTE RECEPTOR POLYPEPTIDES - The claimed invention relates to the discovery of a specific human taste receptor in the T2R taste receptor family, hT2R61 that responds to particular bitter compounds The present invention further relates to the use of this receptor in assays for identifying ligands that modulate the activation of this taste receptor. These compounds may be used as additives and/or removed from foods, beverages and medicinals in order to modify (block) T2R-associated bitter taste. A preferred embodiment is the use of the identified compounds as additives in foods, beverages and medicinals for blocking bitter taste. | 07-21-2011 |
| 20110178273 | METHOD FOR HIGH THROUGHPUT PEPTIDE/PROTEIN ASSAY GENERATION AND ASSAYS GENERATED THEREWITH - The invention relates to a method for the determination of an MRM or SRM assay for a protein of interest, a peptide of interest, or a group of proteins/peptides of interest or a whole proteome. It essentially includes the following steps: (1) a list of proteins of interest is selected and for each member at least one or a list of candidate proteotypic peptides is derived (2) this at least one peptide is synthesized/generated essentially without subsequent purification; (3) this at least one unpurified peptide is analyzed by selected reaction monitoring (SRM) preferably coupled to liquid chromatography (LC-SRM) or analogous techniques; (4) validation and/or optimisation of the corresponding assay of the at least one peptide with determination of the SRM coordinates for a peptide/protein of interest and/or of a regulator of interest is achieved. A protein sample of interest is enzymatically digested and can then be analyzed in SRM mode or time-constrained SRM mode, using elution times to trigger acquisition of the set of selected SRM traces, thus drastically increasing the throughput. The analysis allows to detect and quantify the set of peptides/proteins of interest. The method additionally relates to a tagging strategy to achieve absolute quantification of the peptides/proteins of interest at low-budget and high-throughput. | 07-21-2011 |
| 20110178274 | CANINE TRANSIENT RECEPTOR POTENTIAL V2 (CTRPV2) AND METHODS OF SCREENING FOR TRPV2 CHANNEL MODULATORS - A recombinant canine TRPV2 channel which has been prepared by cDNA cloning and polymerase chain reaction techniques is disclosed. Expression systems for these channels and an assay using the expression systems are also disclosed. The recombinant TRPV2 channel can be used in assays to evaluate compounds which directly or indirectly interact with or bind to TRPV2 channel. | 07-21-2011 |
| 20110196128 | MURINE ZCYTOR17 LIGAND POLYNUCLEOTIDES - The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 08-11-2011 |
| 20110201782 | NOVEL HUMAN GENES RELATING TO RESPIRATORY DISEASES AND OBESITY - This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein. | 08-18-2011 |
| 20110207912 | FGF-19 NUCLEIC ACIDS - The present invention is directed to novel polypeptides having homology to the PRO533 protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention. The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based on the identification of genes that are amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis and/or autocrine signaling. Accordingly, the proteins encoded by the amplified genes are believed to be useful targets for the diagnosis and/or treatment (including prevention) of certain cancers, and may act of predictors of the prognosis of tumor treatment. Furthermore, the compounds, compositions including antagonists and methods of the present invention are further expected to have therapeutic effect upon conditions characterized by FgF-19 modulation. | 08-25-2011 |
| 20110207913 | Induction of Gene Expression Using a High Concentration Sugar Mixture - Described herein is a composition useful for inducing expression of genes whose expression is under control of an inducible promoter sequence and methods for the compositions preparation and use. | 08-25-2011 |
| 20110224406 | INTERLEUKIN-9 RECEPTOR MUTANTS - This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma. | 09-15-2011 |
| 20110230642 | METHOD FOR INCREASING RECLONING EFFICIENCY - The present invention relates to the field of cell culture technology and relates to methods of replicating/cloning cells, preferably cell lines which are important for the production of biopharmaceuticals. The invention also relates to methods of preparing proteins using cells that have been obtained and replicated by single cell deposition and compositions which make it possible to replicate individual cells. | 09-22-2011 |
| 20110230643 | RECOMBINANT FLAGELLIN PROTEIN AND PREPARATION AND USE THEREOF - The present invention provides an optimized recombinant flagellin protein and preparation and use thereof. The protein is with a deletion in the hypervariable region, said hypervariable region is the region from 180 to 400 amino acid of the flagellin protein, and the proteins include FliCΔ190-278, FliCΔ220-320 or FliCΔ180-400. The method of preparing said protein, comprising introducing a deletion into the hypervariable region of the flagellin protein. First constructed the flagellin protein recombinant plasmid, and then used it as template to construct the flagellin deletion cloning, and expressed and purified. The present invention also provides the use of the recombinant flagellin protein as adjuvant. The recombinant flagellin protein in present invention decreases the potential risks it may have, and decreases its antigenicity and immunogenicity and the inflammatory response induced by it, through deleting its main areas of immunogenicity and antigen activity. | 09-22-2011 |
| 20110237777 | FUSION PROTEIN CONTAINING A SINGLE-STRANDED DNA BINDING PROTEIN AND METHODS FOR EXPRESSION AND PURIFICATION OF THE SAME - The present invention provides an expression vector comprising a promoter and a polynucleotide sequence encoding a fusion protein. The present invention further provides a method for purification of an interest protein. The present invention also provides a fusion protein comprising a single-stranded DNA binding protein and an interest protein or polypeptide fused directly or indirectly with the COOH-terminus or NH | 09-29-2011 |
| 20110245463 | APPARATUS AND METHOD FOR STRUCTURE-BASED PREDICTION OF AMINO ACID SEQUENCES - The present invention provides methods and apparatus for analyzing a protein structure. | 10-06-2011 |
| 20110245464 | HIGHLY THERMOSTABLE FLUORESCENT PROTEINS - Thermostable fluorescent proteins (TSFPs), methods for generating these and other stability-enhanced proteins, polynucleotides encoding such proteins, and assays and method for using the TSFPs and TSFP-encoding nucleic acid molecules are provided. The TSFPs of the invention show extremely enhanced levels of stability and thermotolerance. In one case, for example, a TSFP of the invention is so stable it can be heated to 99° C. for short periods of time without denaturing, and retains 85% of its fluorescence when heated to 80° C. for several minutes. The invention also provides a method for generating stability-enhanced variants of a protein, including but not limited to fluorescent proteins. | 10-06-2011 |
| 20110245465 | Methods for Detection of Methyl-CpG Dinucleotides - The invention provides methods for enriching methyl-CpG sequences from a DNA sample. The method makes use of conversion of cytosine residues to uracil under conditions in which methyl-cytosine residues are preserved. Additional methods of the invention enable to preservation of the context of me-CpG dinucleotides. The invention also provides a recombinant, full length and substantially pure McrA protein (rMcrA) for binding and isolation of DNA fragments containing the sequence 5′-C | 10-06-2011 |
| 20110263820 | ANTIBODIES AND PROCESSES FOR PREPARING THE SAME - Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins. | 10-27-2011 |
| 20110263821 | PROGNOSIS AND RISK ASSESSMENT IN STROKE PATIENTS BY DETERMINING THE LEVEL OF MARKER PEPTIDES - The present invention relates to a method for prognosis of an outcome or assessing the risk of a patient having suffered a stroke or a transient ischemic attack, comprising the determination of the level of at least one marker peptide in said sample said marker peptide selected from the group comprising ANP, AVP, ADM, ET-1, troponin, CRP, calcitonin and hGH or fragments thereof or its precursor or fragments thereof and attributing the level of said at least one marker peptides its precursor or fragments thereof with the prognosis of an outcome or assessing the risk for said patient. | 10-27-2011 |
| 20110263822 | COMPOSITION FOR THE PROPHYLAXIS AND TREATMENT OF HBV INFECTIONS AND HBV-MEDIATED DISEASES - The present invention is a composition that comprises at least two hepatitis B virus surface antigens (HBsAgs), fragments thereof and/or nucleic acids encoding them, the HBsAgs differing in HBV genotype in the S region and/or pre-S1 region and the composition containing no HBV core antigen (HBcAg) or nucleic acid encoding that antigen. The present invention also includes pharmaceutical compositions, especially vaccines, comprising these compositions for the prevention and/or treatment of an HBV infection or an HBV-mediated disease. The present invention further includes a method of preparing a patient-specific medicament for the therapeutic treatment of hepatitis B. | 10-27-2011 |
| 20110263823 | ENHANCED CAPACITY AND PURIFICATION OF PROTEIN BY MIXED MODE CHROMATOGRAPHY IN THE PRESENCE OF AQUEOUS-SOLUBLE NONIONIC ORGANIC POLYMERS - This invention relates to the use of mixed mode chromatography for purification of a protein from a mixture containing other materials, including fragmented or aggregated antibodies, host cell proteins, DNA, endotoxin, and/or virus. This invention further relates to the integration of such a method into a multi-step procedure with other fractionation methods for purification of antibodies or other proteins suitable for in vivo applications. | 10-27-2011 |
| 20110269939 | NEW APPROACH FOR DESIGNING DIABETES DRUGS - The present technology relates to the fields of crystallography, biochemistry, and drug design. In particular, methods and compositions for screening, identifying and designing compounds that interact with human mitoNEET. | 11-03-2011 |
| 20110269940 | Self-Assembled Proteins and Related Methods and Protein Structures - The present invention provides user-directed construction of novel specific homo- and hetero-dimeric, and multimeric assemblages of proteins. The present invention is comprised of gene sequences that transcribe peptide sequences that form links between proteins, where the peptide sequences produce a hook or loop which supports specific self-assembly of homo-dimers, hetero-dimers and multimers of the proteins to which they are attached. The hook or loop may have a short aliphatic repeat sequence and a metal binding loop. The present invention also provides a method of constructing a hook motif of metal binding loop sequences that may be attached to at least one aliphatic repeat sequence to produce the assemblages of proteins. Also provided are protein structures produced by the methods of the present invention. | 11-03-2011 |
| 20110269941 | METHOD OF LOADING A CRYSTALLIZATION DEVICE - The present invention pertains to a method for loading a crystallization device and for manufacturing a crystallization device comprising multiple receptacles with a pre-defined amount of at least one matrix-forming compound capable of forming a crystallization matrix for a membrane protein, said method comprising the following steps: a) Modifying the state of aggregation of said at least one matrix-forming compound to a fluidic state which allows dispensing said at least one matrix-forming compound, and b) dispensing a defined amount of said at least one matrix-forming compound into at least one receptacle of the crystallization device, wherein said dispensed matrix-forming compound solidifies within said receptacle. Thereby, pre-filled crystallization devices are obtained which can be used as consumables in particular in automated crystallization processes. Also provided are protein crystallization methods using respectively prepared crystallization devices. | 11-03-2011 |
| 20110282031 | A1 ADENOSINE RECEPTOR DIAGNOSTIC PROBES - This invention relates to a diagnostic probe comprising a compound of formula (I): | 11-17-2011 |
| 20110288272 | MODIFIED CRY3A TOXINS AND NUCLEIC ACID SEQUENCES CODING THEREFOR - Methods for making a modified Cry3A toxin are disclosed. Such methods include the insertion of a protease recognition site that is recognized by a gut protease of a target insect, such as corn rootworm, into at least one position of a Cry3A toxin so that a modified Cry3A toxin is thus designed. The coding sequence of the modified Cry3A toxin may be transformed into a host cell and the host cell grown under conditions that allow the host cell to produce the modified Cry3A toxin. The host cell may be a plant cell and the plant may be comprised in a transgenic plant. Thus, the transgenic plant may be used to produce the modified Cry3A toxin. | 11-24-2011 |
| 20110294981 | CHIMERIC T1R TASTE RECEPTOR POLYPEPTIDES AND NUCLEIC ACID SEQUENCES ENCODING AND CELL LINES THAT EXPRESS SAID CHIMERIC T1R POLYPEPTIDES - The invention relates to compounds that specifically bind a T1R1/T1R3 or T1R2/T1R3 receptor or fragments or sub-units thereof. The present invention also relates to the use of hetero-oligomeric and chimeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet taste stimuli. Further, the invention relates to the constitutive of cell lines that stably or transiently co-express a combination of T1R1 and T1R3; or T1R2 and T1R3; under constitutive or inducible conditions. The use of these cells lines in cell-based assays to identify umami and sweet taste modulatory compounds is also provided, particularly high throughput screening assays that detect receptor activity by use of fluorometric imaging. | 12-01-2011 |
| 20110294982 | AMINO ACID SEQUENCES DIRECTED AGAINST INTEGRINS AND USES THEREOF - The present invention relates to amino acid sequences that are directed against (as defined herein) Integrins, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as | 12-01-2011 |
| 20110294983 | SINGLE-CHAIN ANTIPARALLEL COILED COIL PROTEINS - The present invention relates to single-chain proteins of the formula HRS1-L1-HRS2-L2-HRS3, wherein HRS1, HRS2 and HRS3 are heptad repeat sequences and L1 and L2 are structurally flexible linker sequences, and wherein HRS1, HRS2 and HRS3 form a thermodynamically stable triple-stranded, antiparallel, alpha-helical coiled coil structure in aqueous solution. The invention also relates to amino acid sequence variants, conditions and methods to obtain such proteins and variants, and us ages thereof, especially their usage as scaffolds and as therapeutic products. | 12-01-2011 |
| 20110301328 | POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 12-08-2011 |
| 20110306751 | Independently Inducible System of Gene Expression - The present invention is directed to the improved methods for the temporal induction of proteins using the condensed single protein production (cSPP) system. | 12-15-2011 |
| 20110319595 | FLAGELLIN RELATED POLYPEPTIDES AND USES THEREOF - The use of flagellin and flagellin related polypectides for the protection of mammals from the effects of apoptsis is described. | 12-29-2011 |
| 20120004395 | Use Of Serine Protease Inhibitors In The Treatment Of Neutropenia - The invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment of neutropenia comprising the administration to a subject in need thereof of a therapeutically effective amount of a serine protease inhibitor. The invention also comprises prevention of apoptosis of myeloid cells (1) during and after transfection of bone marrow cells performed for gene therapy, (2) during blood stem cell mobilization performed for reconstitution of hematopoiesis and (3) during infusion of cells of the myeloid lineage for reconstitution of hematopoiesis for gene therapy or for treatment of neutropenia by infusion of neutrophils. | 01-05-2012 |
| 20120010385 | SPLICE VARIANTS OF HUMAN G-PROTEIN COUPLED RECEPTOR HGPRBMY29 (HGPRMBY29SV2) - The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention. | 01-12-2012 |
| 20120010386 | RECOMBINANT MELUSIN FUSION PROTEIN AS PHARMACOLOGICAL AGENT IN THE TREATMENT OF HEART PATHOLOGIES AND COMPOSITIONS THEREOF - A recombinant melusin fusion protein having an improved stability and a capability to reach intracellular compartments as compared to recombinant melusin in vivo, wherein said protein comprises i) a human melusin protein having the amino acid sequence as defined in SEQ ID No.:1, or a homologue thereof having at least 60%, preferably at least 80%, more preferably at least 90% sequence identity to SEQ ID No.:1 and having the function of native melusin protein or a human melusin portion derived from SEQ ID No.:1 or homologue thereof having at least 60%, preferably at least 80%, more preferably at least 90% sequence identity of the melusin portion derived from SEQ ID No.:1 and having the function of native melusin protein and ii) a cell penetrating polypeptide. | 01-12-2012 |
| 20120022232 | CELLS FOR INCREASED PROTEIN EXPRESSION COMPRISING ONE OR MORE RELEASE FACTORS AND METHODS OF USE - The invention provides recombinant cells or recombinant restrictive cells for overexpressing one or more proteins comprising one or more release factors. The invention also provides methods for producing a recombinant protein comprising culturing the cells of the present invention under conditions such that one or more proteins are overexpressed, and then isolating the expressed recombinant protein, In certain embodiments of the present invention, the gene encoding the protein is codon optimized. | 01-26-2012 |
| 20120029169 | METHODS AND COMPOSITIONS COMPRISING TAU OLIGOMERS - Tau protein has a causative role in Alzheimer's disease and multiple other neurodegenerative disorders exhibiting tau histopathology collectively termed tauopathies. The primary function of tau protein is to facilitate assembly and maintenance of microtubules in neuronal axons. In the disease process tau protein becomes modified, loses its affinity to microtubules and accumulates in the cell body where it forms aggregates. The large neurofibrillary tangles formed from tau protein assembled into filaments were thought to be the pathological structure of tau. However, more recent work indicates that smaller, soluble oligomeric forms of tau are best associated with neuron loss and memory impairment. Here, novel compositions of tau oligomers and novel mechanisms for tau oligomer nucleation, extension and termination are taught. Methods for producing and purifying these structures for the development of small molecule and immunotherapeutics as well as antibodies for biomarkers of neurodegenerative diseases are taught. | 02-02-2012 |
| 20120041175 | NOVEL AUTOGRAPHY REGULATORS ATG14L AND RUBICON - The present invention provides for up- and down-regulation of cellular autophagy, e.g., for treating cancer or neurological disease. The invention results, in part, from discovery of two novel proteins, ATG14L (previously called “BISC”) and Rubicon (previously called “BIRC”), which bind to a Class III phophatidylinositol 3′-kinase (PI3K)/Vps34-Beclin 1 autophagic complex. ATG14L and Rubicon each regulate autophagic activity in an opposing manner. ATG14L and Rubicon can be used, for example, to increase/decrease autophagic activity, to increase/decrease PI3K/Vps34 kinase activity, and in so doing, treat diseases and disorders, such as cancer, neurodegenerative disease, stroke, metabolic disease, and age-related disease. ATG14L can increase autophagic activity and PI3K/Vps34 kinase activity; and Rubicon can decrease autophagic activity and PI3K/Vps34 kinase activity. | 02-16-2012 |
| 20120041176 | UCP4 - The present invention is directed to novel polypeptides having homology to certain human uncoupling proteins (“UCPs”) and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention. | 02-16-2012 |
| 20120046446 | p16 MEDIATED REGULATION OF NMDA RECEPTORS - Discovered is a novel protein and variants thereof whose activity at the NMDA receptor causes an increased efflux of calcium ions through the channel of said receptor. This activity is downregulated by the NR3A subunit of NMDA. Also discovered are the nucleic acid sequences encoding said novel protein and variants thereof. The discovery is useful for the diagnosing of NMDA receptor dysregulation and the treatment of NMDA receptor dysregulation related disorders. In addition, the discovery is useful for the further discovery of modulators affecting the activity of the novel protein and variants thereof at the NMDA receptor. | 02-23-2012 |
| 20120059150 | METHODS FOR THE PRODUCTION OF APOLIPOPROTEINS IN TRANSGENIC PLANTS - Methods for the production of an apolipoprotein in plants are described. In one embodiment, the present invention provides a method for the expression of apolipoprotein in plants comprising:
| 03-08-2012 |
| 20120059151 | Non-Functional P2X7 Receptor - The present invention provides antibodies that specifically bind to P2X | 03-08-2012 |
| 20120065371 | Recombinant proteins from filoviruses and their use - Filovirus subunit protein immunogens are produced using a recombinant expression system and combined with one or more adjuvants in immunogenic formulations. The subunit proteins include GP95, GP-FL, VP40, VP24, and NP derived from Ebola Virus and Marburg Virus. Adjuvants include saponins, emulsions, alum, and dipeptidyl peptidase inhibitors. The disclosed immunogenic formulations are effective in inducing strong antibody responses directed against individual Filovirus proteins and intact Filovirus particles as well as stimulating cell-mediated immune responses to the Filoviruses. | 03-15-2012 |
| 20120065372 | DRAGLINE PROTEIN - To provide a new natural fiber material with excellent physical properties. Any one of the following nucleic acids (a) to (d): (a) a nucleic acid having a base sequence of SEQ ID NO: 1 or 19; (b) a nucleic acid encoding a protein having an amino acid sequence of SEQ ID NO: 2 or 20; (c) a nucleic acid encoding a dragline protein and having a sequence identity of 90% or more with the nucleic acid (a); (d) a nucleic acid which encodes a dragline protein and hybridizes with a complementary chain of the nucleic acid (a) under stringent conditions. | 03-15-2012 |
| 20120065373 | DENGUE VACCINE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND NUCLEOTIDE SEQUENCE - The present invention relates to a dengue vaccine, a pharmaceutical composition including the same, and a nucleotide sequence. The dengue vaccine includes N and C termini-deleted nonstructural protein ΔNC NS1 with a peptide fragment from amino acids 36 to 270, which is derived from dengue virus nonstructural protein 1 (DV NS1) with deletions of N-terminal region from amino acids 1 to 35 and C-terminal region from amino acids 271 to 352. The dengue vaccine of the present invention is depleted of cross-reactivity with endothelial cells and platelets, and can shorten the bleeding time. | 03-15-2012 |
| 20120065374 | DENDRITIC CELL CO-STIMULATORY MOLECULES - A novel costimulatory protein molecule, B7-DC, which is a member of the B7 family, is described as is DNA coding therefor and expression vectors comprising this DNA. B7-DC protein, fragments, fusion polypeptides/proteins and other functional derivatives, and transformed cells expressing B7-DC are useful in vaccine compositions and methods. Compositions and methods are disclosed for inducing potent T cell mediated responses that can be harnessed for anti-tumor and anti-viral immunity. | 03-15-2012 |
| 20120071629 | APPOPTOSIN AND USES THEREOF FOR TREATING NEURODEGENERATIVE DISEASE AND CANCER - Disclosed herein are compositions and methods relating to the modulation of Appoptosin levels or activity in the treatment of Neurodegenerative disorders or cancer. | 03-22-2012 |
| 20120071630 | Nucleic Acid and Amino Acid Sequences of Infectious Salmon Anaemia Virus and Their Use as Vaccines - The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, or substantially homologous sequences. These nucleic acid sequences are transcripted and translated into peptide sequences which are incorporated into a vaccination strategy to induce and immune response to the surface antigens of ISAV and therefore ISAV itself. Therefore both the use of a vaccine against ISAV, and the incorporation of peptide sequences is herein described. | 03-22-2012 |
| 20120071631 | Isolation and Characterization of Novel Green Fluorescent Proteins from Copepods - The isolation and characterization of two protein isoforms collected green fluorescent copepods is described herein. The new | 03-22-2012 |
| 20120077960 | FLUOROBODIES: INTRINSICALLY FLUORESCENT BINDING LIGANDS - Binding ligands with intrinsic fluorescence (“fluorobodies”), fluorobody libraries, and methods of preparing fluorobodies are provided. In one aspect, the invention provides fluorobodies generated from a highly stable, artificial fluorescent protein, eCGP123 and derivatives thereof. | 03-29-2012 |
| 20120095188 | ESTABLISHMENT OF INDUCED PLURIPOTENT STEM CELL USING CELL-PERMEABLE REPROGRAMMING TRANSCRIPTION FACTOR FOR CUSTOMIZED STEM CELL THERAPY - The present invention relates to a reprogramming transcription factor recombinant protein in which a macromolecule transduction domain (MTD) is fused to a reprogramming transcription factor to obtain cell permeability. The present invention also relates to a polynucleotide for coding said reprogramming transcription factor recombinant protein and to an expression vector of said cell-permeable reprogramming transcription factor recombinant protein. Treating a somatic cell with the cell-permeable reprogramming transcription factor recombinant protein induces the reprogramming of the stem cell-specific gene of the somatic cell, and thus can be effectively used in the establishment of an induced pluripotent stem cell (iPS cell) having characteristics similar to those of an embryonic stem cell in terms of morphology and genetics. | 04-19-2012 |
| 20120108789 | High affinity binding site of HGFR and methods for identification of antagonists thereof - Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor. | 05-03-2012 |
| 20120108790 | Truncated Somatostatin Receptors - The present invention is directed to fusion proteins that can be used to assay gene transfer and expression both in vitro and in vivo. The fusion proteins contain a reporter protein, e.g. a somatostatin receptor, fused to a second protein, which may be a protein fusion tag. Alternatively, a fusion protein may be fused to a leader sequence. A leader sequence may localize an expressed protein, e.g. localize a fusion protein to the cell membrane. The invention includes nucleic acids encoding the fusion proteins and methods of assaying for gene expression. | 05-03-2012 |
| 20120108791 | Rotamer Libraries and Methods of Use Thereof - Rotamer libraries and methods of use thereof are provided. | 05-03-2012 |
| 20120108792 | PROCESS AND SYSTEM FOR OBTAINING BOTULINUM NEUROTOXIN - Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use. | 05-03-2012 |
| 20120116052 | Nucleic Acid Molecules Encoding TNF-Alpha Ligand Polypeptides Having a CD154 Domain - The present invention is directed to an isolated polynucleotide sequence encoding a chimeric TNFα, comprising a first nucleotide sequence encoding a domain or subdomain of a tumor necrosis factor ligand other than TNFα, wherein the encoded domain or subdomain replaces a cleavage site of native TNFα, and a second nucleotide sequence encoding a domain or subdomain of native TNFα that binds to a TNFα receptor. The encoded chimeric TNFα is significantly less susceptible to cleavage from the cellular surface and, as a result can increase the concentration of a ligand capable of binding to a TNFα receptor on the surface of a cell. The chimeric TNFα is therefore useful in methods for inducing apoptosis of a cell expressing a TNFα receptor, inducing activation of an immune system cell and treating neoplastic cells, by introducing into the cell of interest an isolated polynucleotide sequence encoding a chimeric TNFα that is expressed on the surface of the cell. | 05-10-2012 |
| 20120116053 | EXPRESSION OF TRIPLE-HELICAL COLLAGEN-LIKE PRODUCTS IN E.COLI - Recombinant bacterial triple-helical collagen-like proteins comprising two or more repetitive sequences of Gly-Xaa-Yaa yielding high-stability polymeric constructs without the need for post-translational modifications and which may incorporate one or more functional domains of biological or structural importance. The polymers are capable of high-yield production for a variety of applications | 05-10-2012 |
| 20120123092 | HUMAN A2A ADENOSINE RECEPTOR CRYSTALS AND USES THEREOF - The invention provides the structure of human A2A adenosine receptor protein bound to an antagonist. Methods of using one or more binding sites and other features of this G-protein coupled receptor to develop new therapeutics are also disclosed. | 05-17-2012 |
| 20120123093 | NOVEL SURFACE ANTIGEN - The invention provides a novel surface polypeptide from | 05-17-2012 |
| 20120123094 | GREENER METHOD FOR THE PRODUCTION OF COPOLYMER 1 - The present invention provides a greener method for the production of polyamino acid random copolymers containing alanine, glutamic acid, lysine and tyrosine. In particular, the present invention provides a greener method for the production of Copolymer 1 or a pharmaceutically acceptable salt thereof via a synthetic route that only requires a single deprotection step. | 05-17-2012 |
| 20120123095 | PROCESS AND SYSTEM FOR OBTAINING BOTULINUM NEUROTOXIN - Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use. | 05-17-2012 |
| 20120136137 | Method and composition for crystallizing G protein-coupled receptors - Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising: a) a first portion of a G-protein coupled receptor (GPCR), where the first portion comprises the TM1, TM2, TM3, TM4 and TM5 regions of the GPCR; b) a stable, folded protein insertion; and c) a second portion of the GPCR, where the second portion comprises the TM6 and TM7 regions of the GPCR. | 05-31-2012 |
| 20120142895 | HOST CELLS AND METHODS OF USE - The present invention provides genetically modified | 06-07-2012 |
| 20120165507 | MUTANT PROTEINS AND METHODS FOR PRODUCING THEM - A method for producing a mutant G-protein coupled receptor (GPCR) with increased stability relative to a parent GPCR, the method comprising making one or more mutations in the amino acid sequence that defines a parent GPCR, wherein (i) the one or more mutations are located within a window of / plus or minus 5 residues, where / is the position of amino acid residue 2.46 in the parent GPCR when the parent GPCR is a Class 1 GPCR, or where / is the position of an equivalent amino acid residue in the parent GPCR when the parent GPCR is a Class 2 or 3 GPCR, and/or (ii) the one or more mutations are located within an amino acid sequence of transmembrane helix 7 in the parent GPCR which amino acid sequence interacts with the window of / plus or minus 5 residues, to provide one or more mutants of the parent GPCR with increased stability. | 06-28-2012 |
| 20120172576 | METHOD AND MARKER FOR SIMPLE TRANSFORMATION AND SELECTION OF RECOMBINANT PROTISTS - The present invention concerns a method for production of genetically modified (recombinant) protists without using negative selection markers, in which an auxotrophic mutant of the protist is produced, this mutant is then transformed with recombinant DNA containing at least one gene for complementation of the corresponding auxotrophy, and the resulting recombinant protist is finally selected on a minimal medium that makes possible growth of only the correspondingly complemented protist. The present invention also concerns an efficient method for production of proteins by protists so modified, in which the gene for the protein being produced is coupled to the marker gene. | 07-05-2012 |
| 20120184712 | HOMOGENOUS POPULATIONS OF MOLECULES - The invention provides populations of molecules that are prepared as, or treated to become, homogeneous for one or more molecular characteristics. In an aspect, the invention relates to molecular weight standards that may be used to determine the molecular weight or apparent molecular weight of uncharacterized molecules, such as proteins and nucleic acids, as well as in other applications. In one aspect, the molecular weight standards are pre-stained. | 07-19-2012 |
| 20120184713 | Compositions and Methods for Modulation of Bone Density and Biomineralization - Compositions and methods for modulating FAM20C kinase action and identifying therapeutic agents for the same are disclosed. | 07-19-2012 |
| 20120190821 | RECOMBINANT SOLUBLE FC RECEPTORS - Recombinant soluble Fc receptors according to the present invention are characterized by the absence of transmembrane domains, signal peptides and glycoslyation. Such Fc receptors can easily be obtained by expressing respective nucleic acids in prokaryotic host ells and renaturation of the obtained inclusion bodies, which procedure leads to a very homogenous and pure product. The products can be used for diagnostic as well as pharmaceutical applications and also for the generation of crystal structure data. Such crystal structure data can be used for the modeling of artificial molecules. A further embodiment comprises coupling the Fc receptors according to the invention to solid materials like chromatography materials that an be used to separate and/or enrich antibodies. | 07-26-2012 |
| 20120190822 | ARTIFICIAL ENTROPIC BRISTLE DOMAIN SEQUENCES AND THEIR USE IN RECOMBINANT PROTEIN PRODUCTION - Compositions and methods for recombinant protein production and, more particularly, fusion polypeptides, polynucleotides encoding fusion polypeptides, expression vectors, kits, and related methods for recombinant protein production. | 07-26-2012 |
| 20120190823 | ARTIFICIAL ENTROPIC BRISTLE DOMAIN SEQUENCES AND THEIR USE IN RECOMBINANT PROTEIN PRODUCTION - Compositions and methods for recombinant protein production and, more particularly, fusion polypeptides, polynucleotides encoding fusion polypeptides, expression vectors, kits, and related methods for recombinant protein production. | 07-26-2012 |
| 20120190824 | METHOD FOR HIGHLY SENSITIVE DETECTION OF PROTEIN-PROTEIN INTERACTION - The present invention intends to provide an assay system using split luciferase that has a remarkably high detection sensitivity. In an embodiment, binding of mutually binding first and second proteins is detected by preparing a first fusion protein comprising the first protein fused with a peptide having the amino acid sequence of amino acid SEQ ID NO: 1 and a second fusion protein comprising the second protein fused with a peptide having an amino acid sequence selected from the group consisting of amino acid SEQ ID NOS: 2 to 6, and allowing the first fusion protein to bind with the second fusion protein to form a complex, and detecting luminescence emitted from the complex. | 07-26-2012 |
| 20120197005 | CONTAINERLESS SYNTHESIS OF AMORPHOUS AND NANOPHASE ORGANIC MATERIALS - The invention provides a method for producing a mixture of amorphous compounds, the method comprising supplying a solution containing the compounds; and allowing at least a portion of the solvent of the solution to evaporate while preventing the solute of the solution from contacting a nucleation point. Also provided is a method for transforming solids to amorphous material, the method comprising heating the solids in an environment to form a melt, wherein the environment contains no nucleation points; and cooling the melt in the environment. | 08-02-2012 |
| 20120202971 | LIGHT ACTIVATED ASSOCIATION OF SPLIT GFP - The disclosure relates to a split GFP protein. The GFP protein includes a truncated strand and a beta strand (β-strand). The truncated GFP and the synthetic β-strand respond to the presence of light by changing an assembly thereof | 08-09-2012 |
| 20120220755 | ORGANIC CATION TRANSPORTER POLYPEPTIDES - Novel genes significantly homologous to organic cation transporters OCT1 and OCT2 have been successfully isolated by screening a fetal gene library by random sequencing. Proteins encoded by these genes function as transporters of various organic cations. | 08-30-2012 |
| 20120226020 | HYBRID AND CHIMERIC POLYPEPTIDES THAT REGULATE ACTIVATION OF COMPLEMENT - A hybrid complement-regulating protein comprises a first functional unit of a first complement regulatory protein having complement regulating properties, a first spacer sequence of at least about 200 amino acids encoding a polypeptide that does not exhibit complement regulating properties and at least a second functional unit attached to the spacer sequence. The second functional unit may be a polypeptide providing a functional unit of a second complement regulatory protein, a polypeptide derived from an immunoglobulin, or a polypeptide that enhances binding of the protein to an animal cell. The hybrid protein may also contain a second spacer sequence and a third functional unit of a complement regulatory protein, a polypeptide derived from an immunoglobulin, and a polypeptide that enhances binding of the protein to an animal cell. The optional third functional unit may be the same or different from the first or second functional units. | 09-06-2012 |
| 20120226021 | Co-Crystallization of ERR-alpha with a Ligand that Forms a Reversible Covalent Bond - The crystal structure of the ligand binding domain of ERR-α in complex with a ligand that forms a reversible thioether bond to Cys325 of ERR-α, methods to measure dissociation rates for ligands that form reversible covalent bonds, and methods to design ligands that form reversible covalent bonds for use as modulators of ERR-α activity are disclosed. The crystal structure and methods provide a novel molecular mechanism for modulation of the activity of ERR-α and provide the basis for rational drug design to obtain potent specific ligands for use as modulators of the activity of this new drug target. | 09-06-2012 |
| 20120226022 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS - The present invention is directed to conjugates of hydrolytically stabilized maleimide-functionalized water soluble polymers and to methods for making and utilizing such polymers and their precursors. | 09-06-2012 |
| 20120232251 | GLUCOSE SENSOR - The invention relates to a glucose binding protein comprising amino acid mutations relative to the wild type sequence at the following positions: (i) H 152, (ii) A213; and (iii) L238 wherein the mutation at position H 152 is H152C. The invention further relates to such a glucose binding protein comprising the mutations H152C, A213R and L238S, in particular when linked to an environmentally sensitive dye such as badan. | 09-13-2012 |
| 20120238726 | Mutant blue fluorescent protein and method of using the same for fluorescence resonance energy transfer and blue fluorescent fish - The present invention discloses a mutant blue fluorescent protein (BFP), mutated by an error-prone PCR method or a DNA shuffling method with using a BFPvv D7 of SEQ ID NO:2 as parents, obtained from a wild type blue fluorescent protein BfgV of SEQ ID NO:1, obtained from | 09-20-2012 |
| 20120245324 | PROCESS FOR OBTAINING BOTULINUM NEUROTOXIN - Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use. | 09-27-2012 |
| 20120253013 | Early Growth Transcription Factors and Their Therapeutic Use - The present invention comprises a nucleotide which encodes a protein, wherein the protein includes an amino acid sequence having at least 95% homology to SEQ ID NO: 1 (Egr3 DNA binding domain), for use in therapy. | 10-04-2012 |
| 20120259093 | EXPRESSION OF SECRETED HUMAN ALPHA-FETOPROTEIN IN TRANSGENIC ANIMALS - The invention features a process of expressing secreted recombinant human alpha-fetoprotein (rHuAFP) in the milk or urine of transgenic mammals. | 10-11-2012 |
| 20120271035 | T1R TASTE RECEPTORS AND GENES ENCODING SAME - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular taste stimulus in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed. | 10-25-2012 |
| 20120271036 | Solution Assay and High Through-Put Screen to Probe Interaction Between Human Cullin-Ring Ligase Complex and HIV-VIF Protein - The present invention relates to large-scale production of ElonginB, ElonginC, Vif, and Cullin5. The present invention provides an assay for screening any agent that inhibits the ability of Vif to bind with Cul5. The invention provides an agent identified by the screening methods and methods of treatment using the identified agent. | 10-25-2012 |
| 20120277408 | HIGH-PURITY PRODUCTION OF MULTI-SUBUNIT PROTEINS SUCH AS ANTIBODIES IN TRANSFORMED MICROBES SUCH AS PICHIA PASTORIS - Methods for producing heterologous multi-subunit proteins in transformed cells are disclosed. In particular, the present disclosure provides improved methods of producing multi-subunit proteins, including antibodies and other multi-subunit proteins, which may or may not be secreted, with a higher yield and decreased production of undesired side-products. In exemplary embodiments, the transformed cells are a yeast, e.g., methylotrophic yeast such as | 11-01-2012 |
| 20120283412 | ORPHAN NUCLEAR RECEPTOR - The present invention relates to a novel human orphan nuclear receptor that binds to a cytochrome P-450 monooxygenase (CYP) promoter and that is activated by compounds that induce CYP gene expression. The invention further relates to nucleic acid sequences encoding such a receptor, to methods of making the receptor and to methods of using the receptor and nucleic acid sequences encoding same. The invention also relates to non-human animals transformed to express the human receptor and to methods of using such animals to screen compounds for drug interactions and toxicities. | 11-08-2012 |
| 20120283413 | CHIMERIC, HYBRID AND TANDEM POLYPEPTIDES OF MENINGOCOCCAL NMB1870 - NMB1870 is a protein in Neisseria meningitidis. Three families of NMB1870 are known. To increase the ability of a NMB1870 protein to elicit antibodies that are cross-reactive between the families, NMB1870 is engineered. Sequences can be substituted from one NMB1870 family into the corresponding position in another family. Proteins of NMB1870 sequences from different families can be joined to each other. | 11-08-2012 |
| 20120289683 | Purified Kunitz Trypsin Inhibitor Proteins Isolated from a Soy Processing Stream - A novel Kunitz-trypsin Inhibitor (KTI) isoform recovered from a processing stream and that has a total KTI protein concentration of at least about 95 wt. % is disclosed, as well as a process for recovering and isolating the purified KTI isoform from a processing stream. | 11-15-2012 |
| 20120302732 | CHIMERIC IMMUNORECEPTOR USEFUL IN TREATING HUMAN CANCERS - The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human maligancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain. | 11-29-2012 |
| 20120309939 | Production of Therapeutic Proteins in Photosynthetic Organisms - The present disclosure relates to methods of expressing therapeutic proteins in photosynthetic organisms and the therapeutic proteins produced by the methods. The therapeutic proteins include high-mobility group box 1 (HMGB1) protein, fibronectin domain (10) (10FN3), fibronectin domain (14) (14FN3), interferon beta (IFNβ), proinsulin and vascular endothelial growth factor (VEGF). The photosynthetic organisms include prokaryotes such as cyanobacteria and eukaryotes such as alga and plants. Transformation of eukaryotes is preferably the plastid genome, more preferably the chloroplast genome. | 12-06-2012 |
| 20120316319 | ARYLETHYNYLXANTHENE DYES - Disclosed are 9-arylethynylxanthenes which possess useful fluorescent properties, and can be used as fluorescent dyes, and labels. | 12-13-2012 |
| 20120316320 | PROCESS OF MANAGED ECOSYSTEM FERMENTATION - The presently disclosed subject matter relates to Managed Ecosystem Fermentation (MEF) which is a continuous microbial process utilizing a managed ecosystem approach employing dozens to thousands of species of microorganisms, occurring in a controlled artificial environment and consuming organic materials without benefit of sterilization. The process of utilizing this fermentation for the consumption of organic materials on a continuous basis is within the scope of this disclosed subject matter. The process of separating chemicals as industrial chemicals from this fermentation on a continuous basis is within the scope of this disclosed subject matter. The process of separating biomass useful as high protein animal feed or fertilizer from this fermentation on a continuous (or semi-continuous) basis is within the scope of this disclosed subject matter. | 12-13-2012 |
| 20120316321 | METHODS FOR IDENTIFYING MARKERS FOR EARLY-STAGE HUMAN CANCER, CANCER PROGRESSION AND RECURRENCE - A method is described to identify secreted proteins identified with stages of malignancy of cancer. The proteins are initially identified by trapping them with a fluorescent protein containing vector that can insert in any gene. The secreted proteins are initially identified by their fluorescence. Secreted proteins identifying tumors with specific degrees of malignancy are isolated to determine if they can serve as markers of cancer progression. | 12-13-2012 |
| 20120322979 | Method of producing recombinant TAT-HOXB4H protein for use as a stimulant of hematopoiesis in vivo - The present invention relates to a new and nonobvious method of producing the C-terminal histidine tagged TAT-HOXB4 fusion protein (TAT-HOXB4H), providing unexpected benefits of increased yield and stability to allow for in vivo administration of this protein, and pharmaceutical composition comprising an effective ingredient, TAT-HOXB4H, having stimulatory activity on the production of hematopoietic cells. More specifically, recombinant TAT-HOXB4H protein enhances engraftment of bone marrow transplants, hematopoietic reconstruction, bone marrow re-population and number of circulating stem cells, particularly after chemotherapy or irradiation. | 12-20-2012 |
| 20120329990 | B7-RELATED NUCLEIC ACIDS AND POLYPEPTIDES USEFUL FOR IMMUNOMODULATION - The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject. | 12-27-2012 |
| 20120329991 | AGENT FOR PREVENTING MUSCLE ATROPHY - A muscle atrophy-preventing agent includes a whey protein hydrolyzate having a molecular weight distribution that is within a range of 10 kDa or less and has a main peak of 200 Da to 3 kDa, an average peptide length (APL) of 2 to 8, a free amino acid content of 20% or less, a branched-chain amino acid content of 20% or more, and an antigenicity equal to or less than 1/100,000th of that of β-lactoglobulin. The muscle atrophy-preventing agent exhibits an excellent muscle atrophy-preventing effect. | 12-27-2012 |
| 20130012687 | INDUCIBLE SELF-CLEAVING PROTEASE TAG AND METHOD OF PURIFYING RECOMBINANT PROTEINS USING THE SAME - A method of purifying a protein is disclosed which entails: a) fusing a site-specific affinity-tagged cysteine protease domain to a target protein to form a tagged fusion protein; b) activating the site-specific cysteine protease domain of the tagged fusion protein by subjecting the site-specific affinity-tagged cysteine protease domain to an inducer, which induces autoprocessing at a cleavage site; thereby releasing untagged target protein; and c) isolating the untagged target protein. | 01-10-2013 |
| 20130023647 | MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN - Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described. | 01-24-2013 |
| 20130035472 | METHOD OF PRODUCING TRANSCRIPTS USING CRYPTIC SPLICE SITES - The invention is directed to a method of preparing a nucleic acid sequence with a modified splice site usage profile, which employs the use of a nucleic acid sequence comprising a cryptic splice donor site. The invention also provides a method of producing an alternate form of an RNA molecule encoded by a nucleic acid sequence, which nucleic acid sequence comprises a cryptic splice donor site, a heterologous nucleic acid sequence, and a splice acceptor site. | 02-07-2013 |
| 20130053544 | PEPTIDE TAG SYSTEMS THAT SPONTANEOUSLY FORM AN IRREVERSIBLE LINK TO PROTEIN PARTNERS VIA ISOPEPTIDE BONDS - The present invention concerns the use of a protein capable of spontaneously forming an isopeptide bond for the development of a peptide tag and binding partner pair wherein said peptide tag and binding partner are capable of covalently binding to each other via an isopeptide bond. The invention also provides a method for developing a peptide tag and binding partner pair which are capable of covalently binding to each other based on a protein which is capable of spontaneously forming an isopeptide bond. Additionally provided are peptide tag and binding partner pairs which are obtainable from isopeptide proteins. Further, specifically developed peptide tags and binding partners are encompassed, together with nucleic acid molecules and vectors which encode those peptides or proteins. | 02-28-2013 |
| 20130053545 | IDENTIFYING COMPONENTS OF A NETWORK HAVING HIGH IMPORTANCE FOR NETWORK INTEGRITY - A computer system ( | 02-28-2013 |
| 20130060007 | METHOD OF PROTEIN REFOLDING WITH ION EXCHANGE RESINS AND THE APPLICATION OF THE SAME - A method for protein refolding using a like-charged ion exchange resins as an additive to facilitate protein refolding. The ion exchange resins mentioned herein includes charged group with the same sign as the target protein to be refolded and the method for refolding an unfolded protein. The method has some advantages described as below: firstly, no new impurity is introduced into the final product of protein due to ion exchange resins used in the present invention is insoluble and easy to remove by settlement or centrifugation, secondly; the key material used in the present invention, ion exchange resins, is easy to recycle after regeneration; thirdly, compared with the refolding method by chromatographic techniques, the current method requires no expensive chromatograph facilities and is simple to perform at lower cost, which is a desirable character for preparative refolding of therapeutic proteins expressed in bacteria as inclusion bodies. | 03-07-2013 |
| 20130066047 | RED-SHIFTED CHANNELRHODOPSINS - Methods and compositions are used to identify and characterize new channelrhodopsins derived from algae and several of which are red-shifted. The rhodopsin domain of these red-shifted channelrhodopsins can be cloned and expressed in mammalian systems and used in optogenetic applications and as therapeutic agents. Also provided are methods and compositions for use in red-shifting the absorbance maxima of channelrhodopsins in order to improve their utility for use in vivo. | 03-14-2013 |
| 20130066048 | Methods of Obtaining Natural Products from the Comestible Fluids and Methods of Use - Described herein is an enriched substance containing a ground edible material comprising one or more concentrated bioactive natural products from plant juice, as well as methods of producing such enriched substances and methods of using such solids to provide beneficial effects to humans or other animals. Enriched foods comprising the enriched substance(s) are also provided. Also provided are non-sorbed natural products such as sugars, fats oils, and carotenoids found in the non-sorbed plant liquor fraction of plant juice. | 03-14-2013 |
| 20130085262 | NOVEL SURFACE ANTIGEN - The invention provides a novel surface polypeptide from | 04-04-2013 |
| 20130085263 | METHOD FOR NON-COVALENT IMMOBILIZATION OF INFECTIOUS PRION PROTEIN - The present invention is method for non-covalently immobilizing an infectious prion protein using a magnetic substrate. | 04-04-2013 |
| 20130085264 | Methods and Reagents for Diagnosing Hantavirus Infection - Novel methods and immunodiagnostic test kits for the detection of hantavirus infection are disclosed. The methods and kits employ combinations of recombinant N and/or G1 antigens from at least six different hantavirus serotypes, including Hantann (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV). Additional hantavirus antigens from these and other hantavirus types may also be present. The methods provide for highly accurate results and allow the detection of infection so that treatment can be administered and death avoided. | 04-04-2013 |
| 20130090454 | Light-Sensitive Ion-Passing Molecules - The invention provides polynucleotides and methods for expressing light-activated proteins in animal cells and altering an action potential of the cells by optical stimulation. The invention also provides animal cells and non-human animals comprising cells expressing the light-activated proteins. | 04-11-2013 |
| 20130096278 | THIOSULFONATE COMPOUND, REVERSIBLE CATIONIZATION AGENT FOR PROTEIN AND/OR PEPTIDE, AND METHOD FOR SOLUBILIZATION - The object of the present invention is to provide a novel thiosulfonate compound, a reversible cationization agent for protein and/or peptide, which can reversibly cationize a wider range of proteins and peptides with high stability of quality and accuracy and which are useful for a high degree of purification and recovery, as well as, a method for solubilization for protein and/or peptide using the agent. | 04-18-2013 |
| 20130116408 | Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy - The invention is directed to novel compositions and methods utilizing virion derived protein nanoparticles for delivery of medical imaging agents and therapeutic agents for the diagnosis and treatment of malignant and systemic diseases. The nanoparticles of the present invention are designed to deliver radioactive isotopes suitable for imaging a tumor and its metastases. Additionally, the nanoparticles may deliver a radioisotope that is suitable for treating a tumor and its metastases by alpha, beta or gamma radiation. Alternatively, the virion derived nanoparticles may deliver a treatment agent for cancer or a combination of a radioisotope and a cancer treatment agent. Additionally the virion derived nanoparticle may include delivery of a drug that enhances the immune system's recognition of the tumor. | 05-09-2013 |
| 20130116409 | Method for Enriching Methylated CpG Sequences - Compositions and methods are provided for facilitating the enrichment of single-stranded DNA containing methylated CpG in a mixture containing methylated and unmethylated DNA. The compositions relate to methylation-binding protein domains that selectively bind to methylated single strand DNA. In embodiments of the invention, the methylated DNA is eluted in 0.4M-0.6M NaCl while the unmethylated single strand DNA is eluted in less than 0.4M salt. The ability to readily enrich for methylated DNA permits high throughput sequencing of the methylated DNA and identification of abnormal methylation patterns associated with disease. | 05-09-2013 |
| 20130123467 | Engineering surface epitopes to improve protein crystallization - The invention provides for methods and systems for engineering target proteins, based on protein sequence characteristics that influence the likelihood of obtaining a crystal suitable for X-ray structure solution, to improve protein crystallization, as well as related material. | 05-16-2013 |
| 20130131315 | AUTO-PROCESSING DOMAINS FOR POLYPEPTIDE EXPRESSION - Embodiments herein include methods and constructs that can be used to co-express two or more polypeptides of interest from a single polynucleotide encoding a precursor polypeptide. Within this precursor polypeptide can reside at least one autonomous processing unit, which can mediate release of flanking polypeptides of interest in cis. The processing unit can include an N-terminal autocatalytic cleavage domain and a C-terminal cleavage domain. Some embodiments include constructs and methods for co-expressing polypeptides without N- or C-terminal overhangs, in any cellular or extracellular location, and/or in stoichiometric ratios. | 05-23-2013 |
| 20130144038 | CRYSTAL STRUCTURE OF A MarR FAMILY POLYPEPTIDE - The crystal structure of the product, crystals of the MarR protein, a regulator of multiple antibiotic resistance in | 06-06-2013 |
| 20130150554 | CELL CULTURE OF GROWTH FACTOR-FREE ADAPTED CELLS - The present invention provides improved cell culture systems that allow optimum production of recombinant proteins. Among other things, the present invention provides methods of cell culture including a step of cultivating cells adapted to growth factor-free medium in a cell culture system that provides at least one growth factor. | 06-13-2013 |
| 20130158235 | SELECTIVE MANUFACTURE OF RECOMBINANT NEUROTOXIN POLYPEPTIDES - The present invention pertains to recombinant neurotoxin polypeptides and the manufacture thereof. Specifically, it relates to a polynucleotide encoding a neurotoxin polypeptide comprising a light chain, a linker and a heavy chain, wherein the linker is a modified linker comprising an heterologous amino acid sequence which confers at least one physicochemical property to the polypeptide which allows for separation of partially processed and/or unprocessed neurotoxin polypeptides from processed neurotoxin polypeptides, said heterologous amino acid sequence being flanked N- and C-terminally by a protease recognition and cleavage site Further encompassed by the present invention are vectors and host cells comprising the polynucleotide of the invention as well as polypeptides encoded by the polynucleotide and methods for the manufacture of processed neurotoxin polypeptide. | 06-20-2013 |
| 20130165633 | Endogenous and Non-Endogenous Versions of Human G Protein-Coupled Receptors - The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown (“orphan GPCR receptors”), and most particularly to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity. | 06-27-2013 |
| 20130190477 | COMPLEMENT RECEPTOR 2 (CR2) TARGETING GROUPS - Provided herein are compositions and methods directed to soluble proteins which can selectively deliver modulators of complement activity. Targeted delivery of these modulators is accomplished by selectively mutating particular amino acids in a targeting protein portion of the composition corresponding to at least the first two N-terminal SCR domains of CR2. Depending on the particular combination of mutations introduced into the targeting portion, a complement activity modulator can be selectively delivered to particular ligands of CR2 at sites where complement system activation or suppression is desired. | 07-25-2013 |
| 20130197192 | Method and Composition for Crystallizing G Protein-Coupled Receptors - Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising: a) a first portion of a G-protein coupled receptor (GPCR), where the first portion comprises the TM1, TM2, TM3, TM4 and TM5 regions of the GPCR; b) a stable, folded protein insertion; and c) a second portion of the GPCR, where the second portion comprises the TM6 and TM7 regions of the GPCR. | 08-01-2013 |
| 20130203961 | Molecular Vaccine Linking an Endoplasmic Reticulum Chaperone Polypeptide to an Antigen - This invention provides compositions and methods for inducing and enhancing immune responses, such as antigen-specific cytotoxic T lymphocyte (CTL) responses, using chimeric molecules comprising endoplasmic reticulum chaperone polypeptides and antigenic peptides. In particular, the invention provides compositions and methods for enhancing immune responses induced by polypeptides made in vivo by administered nucleic acid, such as naked DNA or expression vectors, encoding the chimeric molecules. The invention provides a method of inhibiting the growth of a tumor in an individual. The invention also provides novel self-replicating RNA virus constructs for enhancing immune responses induced by chimeric polypeptides made in vivo. | 08-08-2013 |
| 20130217859 | CHIMERIC, HYBRID AND TANDEM POLYPEPTIDES OF MENINGOCOCCAL NMB1870 - NMB 1870 is a protein in | 08-22-2013 |
| 20130225792 | METHOD OF PRODUCING AND PURIFYING SOLUBLE RECOMBINANT COQ5 PROTEIN AND SOLUBLE RECOMBINANT COQ5 PROTEIN THEREOF - The present invention relates to a producing and purifying method of soluble recombinant COQ5 protein, which is expressed in soluble form by | 08-29-2013 |
| 20130231460 | METHOD AND DEVICE FOR CONCENTRATING TARGET COMPOUNDS - The present invention relates to a method for concentrating one or more target compounds in a liquid sample, a device for carrying out this method and a kit for processing a biological sample comprising such a device. | 09-05-2013 |
| 20130245226 | Antibodies To Non-Functional P2X7 Receptor - The present invention provides antibodies that specifically bind to P2X | 09-19-2013 |
| 20130245227 | METHODS OF ACTIVATING CLOSTRIDIAL TOXINS - The specification discloses modified Clostridial toxins comprising an exogenous Clostridial toxin di-chain loop protease cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins; method of producing such modified Clostridial toxins, method of activating such modified Clostridial toxins and methods of activating recombinantly-expressed Clostridial toxins. | 09-19-2013 |
| 20130274441 | General Method for Designing Self-Assembling Protein Nanomaterials - Methods and systems for computationally designing self-assembling polypeptides are disclosed. A representation of a docked configuration of a symmetric protein architecture can be determined by a computing device configured to computationally symmetrically dock representations of protein building blocks within a representation of a symmetric protein architecture, where symmetrically docking a representation of a particular protein building block can include determining a configuration of the protein building blocks in three-dimensional space within the symmetric protein architecture configured to generate interfaces between building blocks suitable for computational protein interface design. The amino acid sequence of the docked protein building blocks can be computationally modified to specify protein-protein interfaces between the plurality of protein building blocks that are energetically favorable to drive self-assembly of a protein that includes the modified amino acid sequence. | 10-17-2013 |
| 20130274442 | Analyte Sensors, Methods for Preparing and Using Such Sensors, and Methods of Detecting Analyte Activity - Embodiments of the present disclosure provide for analyte sensors, methods for producing and using the analyte sensors, methods of detecting and/or measuring analyte activity, methods for characterizing analyte cellular activity, methods of detecting pH change in a system, method of controlling the concentration of an analyte in a system, fusion proteins, polynucleotides, and vectors corresponding to the analyte sensors, kits, and the like. | 10-17-2013 |
| 20130281666 | METHODS OF ACTIVATING CLOSTRIDIAL TOXINS - The specification discloses modified Clostridial toxins comprising an exogenous Clostridial toxin di-chain loop protease cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins; method of producing such modified Clostridial toxins, method of activating such modified Clostridial toxins and methods of activating recombinantly-expressed Clostridial toxins. | 10-24-2013 |
| 20130289242 | METHOD FOR PRODUCING BIO-ACTIVE AGENT FOR THE PREVENTION OF DISEASE CAUSED BY WHITE SPOT SYNDROME BACULOVIRUS COMPLEX AND A BIO-ACTIVE AGENT DERIVED THEREOF - A method of producing an agent capable of eliciting immune response against White Spot Syndrome Baculovirus complex in crustaceans of Penaeidae family upon ingestion of the agent comprising the steps of introducing a vector containing genetic sequence of Seq. No 1 into an alga to transform the algae; and cultivating the transformed algae to express modified VP28 peptides according to the genetic sequence of Seq. No. 1 to obtain the agent. | 10-31-2013 |
| 20130296532 | VECTORS WITH MODIFIED INITIATION CODON FOR THE TRANSLATION OF AAV-REP78 USEFUL FOR PRODUCTION OF AAV - The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions. The insect cells preferably comprise a first nucleotide sequence encoding the parvoviral rep proteins whereby the initiation codon for translation of the parvoviral Rep78 protein is a suboptimal initiation codon that effects partial exon skipping upon expression in insect cells. The insect cell further comprises a second nucleotide sequence comprising at least one parvoviral (AAV) inverted terminal repeat (ITR) nucleotide sequence and a third nucleotide sequence comprising a sequences coding for the parvoviral capsid proteins. | 11-07-2013 |
| 20130331546 | ANNEXIN II COMPOSITIONS AND METHODS - The present invention provides compositions and methods that involve the 36 kDa annexin II monomer, which has been identified as having immunostimulatory properties. Accordingly, in one aspect, the invention provides compositions that include at least one 36 kDa annexin II monomer or an immunomodulatory fragment thereof. In another aspect, the invention provides methods that include administering to a subject a composition that includes at least one 36 kDa annexin II monomer or an immunomodulatory fragment thereof. In another aspect, the invention provides methods that induce an in situ increase in the 36 kDa annexin II monomer by administering to a subject an amount of composition effective to induce localized hypoxia sufficient to cause a localized increase in annexin II. | 12-12-2013 |
| 20130331547 | TRANSGENE DELIVERING RETROVIRUS TARGETING COLLAGEN EXPOSED AT SITE OF TISSUE INJURY - A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component. | 12-12-2013 |
| 20130331548 | COMPOSITIONS OF FLAGELLIN AND PAPILLOMAVIRUS ANTIGENS - Compositions that include at least one protein that activates a Toll-like Receptor and includes at least a portion of at least one Toll-like Receptor agonist and at least a portion of at least one papillomavirus suppressor binding protein, papillomavirus transforming protein and papillomavirus capsid protein can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can further include an adjuvant and a carrier protein. | 12-12-2013 |
| 20130345398 | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy - The present invention relates to the construction, expression, and purification of synthetic or recombinant light chain (LC) | 12-26-2013 |
| 20130345399 | METHOD OF EXPRESSING PROTEINS WITH DISULFIDE BRIDGES - This invention relates to methods of expressing eukaryotic proteins in prokaryotic hosts, particularly eukaryotic proteins that require formation of disulfide bridges for biological activity. Various approaches are used including fusion to thioredoxin, cytoplasmic expression of disulfide isomerases, deficiencies in thioredoxin and/or glutathione reductases, deficiencies in proteases, and the like. The method is applicable to express monomeric and dimeric forms of the eukaryotic protein with biological activity such as monomeric and dimeric forms of a disintegrin or a disintegrin domain. Included are the vectors, host cells expressing the proteins, the expressed proteins and methods of using the proteins. | 12-26-2013 |
| 20130345400 | IDENTIFICATION OF A HUMAN GYROVIRUS AND APPLICATIONS - The present invention relates to HGyV, a human gyrovirus related to the chicken anemia virus (CAV). The present invention also relates to a new proteins encoded by HGyV, which proteins display some homology to CAV proteins. Among these new proteins, H-apoptin is of particular interest as it is herein found for the first time in a human virus and can be used for treating cancer. Also provided are methods for detecting the HGyV virus in a subject. | 12-26-2013 |
| 20140005360 | Polypeptides and Immunizing Compositions Containing Gram Positive Polypeptides and Methods of Use | 01-02-2014 |
| 20140031525 | MUTANT G-PROTEIN COUPLED RECEPTOR PROTEINS AND METHODS FOR PRODUCING THEM - A method for producing a mutant G-protein coupled receptor (GPCR) with increased stability relative to a parent GPCR, the method comprising making one or more mutations in the amino acid sequence that defines a Class 1 parent GPCR, wherein (i) the one or more mutations are located within a window of i plus or minus 5 residues, where i is the position of amino acid residue 3.55 in the parent GPCR, and/or (ii) the one or more mutations are located within a window of i minus 2 to i residues, where i is the position of amino acid residue 5.63 in the parent GPCR, and/or (iii) the one or more mutations are located within a window of i minus 4 to i plus 1 residues, where i is the position of amino acid residue 7.42 in the parent GPCR, to provide one or more mutants of the parent GPCR with increased stability. | 01-30-2014 |
| 20140039156 | HIGH-THROUGHPUT SCREENING FOR COMPOUNDS MODULATING EXPRESSION OF CELLULAR MACRO-MOLECULES - A method of screening for compounds that module expression of specific macromolecules, the “target”. The method is particularly useful in that it does not require separation of target-bound and excess ligand and therefore enables, but is not limited to, High Throughput Screening for compounds that increase or decrease the levels or amounts of a target present in a biological sample. The method can also be used for high-throughput diagnosis of a condition leading to an increase or decrease of a cellular macromolecule. | 02-06-2014 |
| 20140039157 | METHODS AND COMPOSITION FOR MEASURING THE AMOUNT OF VITAMIN D DERIVATIVES - Methods and compositions for measuring the amount of vitamin D derivatives are disclosed. Fluorescence Resonance Energy Transfer (FRET) in combination with a modified ligand-binding domain of the vitamin D receptor (LBD-VDR) to measure vitamin D derivatives are also disclosed. | 02-06-2014 |
| 20140046024 | EVALUATION OF COPOLYMER DIETHYLAMIDE - Methods of analyzing glatiramer acetate (GA) or a polymeric precursor thereof are provided. The methods can include determining a level of one or more diethylamide-modified amino acids in a sample comprising GA or a polymeric precursor thereof, and selecting at least a portion of the sample based on the assessment of the one or more diethylamide-modified amino acids in the sample. | 02-13-2014 |
| 20140046025 | DEVICE AND METHOD FOR PRODUCTION AND ANALYSIS OF PRIONS - The invention provides a method for producing prion protein having an aggregated conformation by contacting native conformation prion protein with aggregated conformation prion protein in a liquid preparation and subjecting this to at least one cycle or to a number of cycles of application of shear-force for fragmenting aggregates of prion protein, wherein the shear-force applied is precisely controlled. In addition to this process for amplification of aggregated state prion protein from native conformation prion protein, the invention relates to the aggregated state prion protein obtained by the amplification process, which aggregated state prion protein has one conformation, which is e.g. identical within one batch and reproducible between batches, e.g. as detectable by proteinase resistance in a Western blot. | 02-13-2014 |
| 20140051829 | AXMI-205 PESTICIDAL GENE AND METHOD FOR ITS USE - Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for pesticidal polypeptides are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated pesticidal nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed. In particular, the present invention provides for nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:2, 3, or 4, the nucleotide sequence set forth in SEQ ID NO:1, 9, 10, or 11, as well as variants and fragments thereof. | 02-20-2014 |
| 20140051830 | In-Process Control for the Manufacture of Glatiramer Acetate - The present disclosure provides methods for manufacturing or producing glatiramer acetate having a Mp of 5000-9000 Da. These methods include: polymerizing N-carboxy anhydrides of L-alanine, benzyl-protected L-glutamic acid, trifluoroacetic acid (TFA)-protected L-lysine, and L-tyrosine to generate a sample comprising intermediate-1; treating the sample comprising intermediate-1 to partially depolymerize the protected copolymer and deprotect benzyl-protected L-glutamic acid, measuring the viscosity of the sample comprising intermediate-1 during the treatment, and ending the treatment when the viscosity of the sample is within an endpoint range, thereby generating a sample comprising intermediate-2; treating the sample comprising intermediate-2 to deprotect TFA-protected L-lysine, thereby generating intermediate-3; further processing the intermediate-3 to generate a sample glatiramer acetate; and purifying the glatiramer acetate to generate a composition comprising purified glatiramer acetate having a Mp of 5000-9000 Da. | 02-20-2014 |
| 20140058065 | FAR-RED FLUORESCENT PROTEINS WITH IMPROVED DETECTABILITY BY RED EXCITATION LIGHT - Aspects of the present disclosure are directed towards far-red monomeric fluorescent proteins that have a high level of brightness such that the proteins are visible over the autofluorescence aspects of tissue. In certain embodiments, the fluorescent proteins are derived from | 02-27-2014 |
| 20140066595 | Modulators of Protein Production in a Human Cell Line and Cell-free Extracts Produced Therefrom - Cell-free extracts, methods for producing these extracts, methods for using these extracts, compositions that facilitate production of these extracts and kits that contain these extracts are provided. By increasing or decreasing certain gene products through, for example, the use of siRNA or mimics, one can develop mammalian cell-free extracts that have desired levels of efficiency. | 03-06-2014 |
| 20140073764 | UNNATURAL AMINO ACIDS COMPRISING A CYCLOOCTYNYL OR TRANS-CYCLOOCTENYL ANALOG GROUP AND USES THEREOF - The present invention relates to unnatural amino acids comprising a cyclooctynyl or trans-cyclooctenyl analog group and having formula (I) or an acid or base addition salt thereof. The invention also relates to the use of said unnatural amino acids, kits and processes for preparation of polypeptides that comprise one or more than one cyclooctynyl or trans-cyclooctenyl analog group. These polypeptides can be covalently modified by in vitro or in vivo reaction with compounds comprising an azide, nitrile oxide, nitrone, diazocarbonyl or 1,2,4,5-tetrazine group. | 03-13-2014 |
| 20140073765 | REGENERATION AND REPAIR OF MESENCHYMAL TISSUE USING AMELOGENIN - A method of treating an injury to or a disease of a skeletal joint ligament is disclosed. The method comprises contacting the skeletal joint ligament or tendon of the subject with a therapeutically effective amount of amelogenin, wherein the amelogenin is not comprised in a scaffold, thereby treating the injury to or disease of the skeletal joint ligament or tendon. | 03-13-2014 |
| 20140088292 | Water-Soluble Polypeptides Comprised of Repeat Modules, Method for Preparing the Same and Method for a Target-Specific Polypeptide and Analysis of Biological Activity Thereof - The present invention relates to a soluble polypeptide comprised of repeat modules. More particularly, the present invention relates to a soluble fusion polypeptide of the N-terminal domain of internalin and LRR (Leucine rich repeat) family protein, a method for preparing the polypeptide, a vector comprising a nucleic acid sequence encoding the polypeptide, a host cell comprising the vector, a method for producing a solubility and folding-improved fusion polypeptide by expressing the vector in the host cell, and a method for improving the solubility and folding of the fusion polypeptide. Further, the present invention relates to a method for preparing the polypeptide bound with a specific target and analyzing the efficacy of the soluble polypeptide. | 03-27-2014 |
| 20140094587 | FILAMENTOUS FUNGI HAVING AN ALTERED VISCOSITY PHENOTYPE - Described are compositions and methods relating to variant filamentous fungi having altered growth characteristics. Such variants are well-suited for growth in submerged cultures, e.g., for the large-scale production of enzymes and other proteins for commercial applications. | 04-03-2014 |
| 20140100357 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES - Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one aromatic amine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one alkylated amine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses. | 04-10-2014 |
| 20140121356 | HYPOALLERGENIC MUTANT POLYPEPTIDES BASED ON FISH PARVALBUMIN - The present invention relates to non-naturally occurring polypeptides derived from fish allergens such as parvalbumin Cyp c 1.01 from carp. The polypeptides display reduced allergenic activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination. | 05-01-2014 |
| 20140142281 | METHOD FOR PRODUCING ANTIMICROBIAL CELLULOSE FIBER, FIBER PRODUCED BY THE METHOD AND FABRIC USING THE FIBER - A method for producing an antimicrobial cellulose fiber. The method includes reacting a reactive compound with an antimicrobial agent to prepare a reactive antimicrobial compound, chemically fixing the reactive antimicrobial compound to a cellulose fiber through chemical bonding between the reactive compound and the cellulose fiber, and stabilizing the cellulose fiber structure. Further disclosed is an antimicrobial cellulose fiber produced by the method. The antimicrobial cellulose fiber is a human friendly material that has excellent antimicrobial activity and deodorizing performance. The antimicrobial cellulose fiber can be manufactured in the form of raw cotton, sliver, roving yarn, spun yarn, woven fabric, knitted fabric, non-woven fabric, etc. The antimicrobial cellulose fiber may be blended with other fibers, such as natural fibers and synthetic fibers. | 05-22-2014 |
| 20140142282 | Method for Processing Thin Stillage and Apparatus for Producing a Protein Containing Product - A method for processing thin stillage (TS), characterized by the following steps: a) feeding of thin stillage (TS) into a working vessel ( | 05-22-2014 |
| 20140148575 | BIODEGRADABLE ELECTROCONDUCTING NANOWIRE, METHOD OF MANUFACTURE AND USES THEREOF - The subject matter of the invention is an electroconducting nanowire, comprising an amyloid fibre which results from the self-assembling of peptides comprising a prion domain or a derivative of this domain and which is functionalized by electron transporting peptides, each comprising amino acids bound to one or more atoms of iron. | 05-29-2014 |
| 20140148576 | Traceless Ubiquitination - The invention related to a tRNA synthetase capable of binding delta-substituted lysine, wherein said tRNA synthetase comprises amino acid sequence corresponding to the amino acid sequence of at least L271 to Y349 of MbPyIRS, wherein said sequence comprises 5 or fewer substitutions within the amino acid sequence corresponding to the amino acid sequence of at least L271 to Y349 of MbPyIRS; and wherein said synthetase comprises W at amino acid position 349 relative to MbPyIRS. | 05-29-2014 |
| 20140148577 | METHOD FOR IMMOBILIZING PROTEIN A ON A SELF-ASSEMBLED MONOLAYER - The object of the present invention is to provide a method for increasing an amount of Protein A to be immobilized on the self-assembled monolayer. Immobilizing Protein A to the self-assembled monolayer through the structure represented following formula (II) obviates the object. | 05-29-2014 |
| 20140155578 | VARIANT SUCROSE TRANSPORTER POLYPEPTIDES - Variant sucrose transporter polypeptides that enable bacterial growth over a wide range of gene expression levels and sucrose concentrations are described. Additionally, recombinant bacteria comprising these variant sucrose transporter polypeptides, and methods of utilizing the bacteria to produce products such as glycerol and glycerol-derived products are provided | 06-05-2014 |
| 20140171620 | CILIARY NEUROTROPHIC FACTOR VARIANTS - Nucleic acid molecule selected from the group consisting of (a) a nucleic acid molecule having a nucleotide sequence shown in SEQ ID: NO 1, (b) a nucleic acid molecule which encodes a peptide having an amino acid sequence shown in SEQ ID: NO 2, (c) a nucleic acid molecule whose complementary strand hybridizes to a nucleic acid molecule according to (a) or (b) and which codes for a peptide which binds to ciliary neurotrophic factor receptor (CNTFR), the peptide binding with lower affinity than ciliary neurotrophic factor to the interleukin-6 receptor (IL-6R), (d) a nucleic acid molecule whose nucleotide sequence differs from the nucleotide sequence of a nucleic acid molecule according to (c) due to the degenerated genetic code, the codon at positions 82-84 of the nucleic acid molecule according to (a) coding for a non-positively charged amino acid, and the peptide at position 28 shown in SEQ ID: NO 2 having a non-positively charged amino acid residue. | 06-19-2014 |
| 20140187748 | MIRAC PROTEINS - This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures. | 07-03-2014 |
| 20140194595 | Method and Composition for Crystallizing G Protein-Coupled Receptors - Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising: a) a first portion of a G-protein coupled receptor (GPCR), where the first portion comprises the TM1, TM2, TM3, TM4 and TM5 regions of the GPCR; b) a stable, folded protein insertion; and c) a second portion of the GPCR, where the second portion comprises the TM6 and TM7 regions of the GPCR. | 07-10-2014 |
| 20140206843 | Therapeutic TRAIL Fusion Protein and Preparation and Use Thereof - This invention relates to the biotechnology area, and provides a kind of TRAIL chimeric protein, DNA sequence encoding this chimeric protein, vectors comprising this DNA, host cells or transgenic animals that contain one of the vectors, and preparation methods for the said chimeric protein and its applications. The said TRAIL fusion protein from the N to C terminal comprises human leucine zipper sequence, human TRAIL protein, human TRAIL extracellular domain or a fragment thereof. The chimeric protein has significantly enhanced stability, prolonged half-life in animals, increased efficacy and thus has broad application future. | 07-24-2014 |
| 20140213762 | CASEIN HYDROLYSATE - A casein hydrolysate formed by controlled hydrolysis of a casein substrate by an | 07-31-2014 |
| 20140213763 | LACTIC ACID BACTERIA STRAIN AND ITS USE FOR THE PROTECTION OF FOOD PRODUCTS - The present invention refers to a strain of | 07-31-2014 |
| 20140221613 | NOVEL MODIFIED PROTEIN COMPRISING TANDEM-TYPE MULTIMER OF MUTANT EXTRACELLULAR DOMAIN OF PROTEIN G - The purpose of the present invention is: to provide an excellent protein which is further reduced in the binding property to an Fc region of an immunoglobulin and/or the binding property to an Fab region of the immunoglobulin in a weakly acidic region compared with that of a protein containing an extracellular domain of wild-type protein G, and which still keeps a high antibody-binding activity in a neutral region; and to capture and collect an antibody readily using the protein without denaturating the antibody. The present invention relates to: a protein that is reduced in the binding property to an Fc region of an immunoglobulin and/or the binding property to an Fab region of the immunoglobulin in a weakly acidic region compared with that of a multimer comprising an extracellular domain of wild type one, which is a domain having a binding activity to a protein comprising an Fc region of immunoglobulin G, while keeping a high antibody-binding activity in a neutral region, and also has a binding activity to a protein comprising the Fc region of immunoglobulin G, wherein the protein comprises a tandem-type multimer of a mutant of the extracellular domain; and others. | 08-07-2014 |
| 20140235823 | FUSION PROTEIN CONTAINING A SINGLE-STRANDED DNA BINDING PROTEIN AND METHODS FOR EXPRESSION AND PURIFICATION OF THE SAME - The present invention provides an expression vector comprising a promoter and a polynucleotide sequence encoding a fusion protein. The present invention further provides a method for purification of an interest protein. The present invention also provides a fusion protein comprising a single-stranded DNA binding protein and an interest protein or polypeptide fused directly or indirectly with the COOH-terminus or NH | 08-21-2014 |
| 20140249295 | LIGHT-INDUCIBLE SYSTEM FOR REGULATING PROTEIN STABILITY - Disclosed herein are a light-inducible system and method for rapidly and reversibly modulating protein stability and function. This system and method employs conditionally stable protein domains that regulate the degradation of a fusion protein depending upon the presence or absence of a particular light source. | 09-04-2014 |
| 20140256913 | MSP NANOPORES AND RELATED METHODS - Provided herein are | 09-11-2014 |
| 20140288270 | ISOLATED CHROMOPROTEIN OF STICHODACTYLA HADDONI - The present application provides a chromoprotein (shCP), comprising amino acid sequences with greater than 96% consistency of SEQ ID NO: 1. The chromoprotein is derived from | 09-25-2014 |
| 20140296486 | NOVEL AAV'S AND USES THEREOF - The invention in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the invention relates to gene transfer methods using the recombinant adeno-associate viruses. In some aspects, the invention relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same. | 10-02-2014 |
| 20140303345 | GPCR Fusion Protein Containing an N-Terminal Autonomously Folding Stable Domain, and Crystals of the Same - Certain embodiments provide a GPCR fusion protein. In particular embodiments, the GPCR fusion protein comprises: a) a G-protein coupled receptor (GPCR); and b) an autonomously folding stable domain, where the autonomously folding stable domain is N-terminal to the GPCR and is heterologous to the GPCR. The GPCR fusion protein is characterized in that is crystallizable under lipidic cubic phase crystallization conditions. In certain embodiments, the GPCR fusion protein may be crystallizable in a complex with a G-protein or in a complex with an antibody that binds to the IC3 loop of the GPCR. | 10-09-2014 |
| 20140309402 | MSP NANOPORES AND RELATED METHODS - Provided herein are | 10-16-2014 |
| 20140323691 | Isopeptide Bond Formation in Bacillus Species and Uses Thereof - A mechanism for a unique isopeptide bond formation between polypeptides is disclosed as well as sequence motifs used in such bond formation and methods of using such sequence motifs. | 10-30-2014 |
| 20140323692 | Development of Sensitive FRET Sensors and Methods of Using the Same - Intramolecular biosensors are disclosed, including PBP-based biosensors, comprising a ligand binding domain fused to donor and fluorescent moieties that permit detection and measurement of Fluorescence Resonance Energy Transfer upon binding ligand. At least one of the donor and fluorescent moieties may be internally fused to the biosensor such that both ends of the internally fused fluorophore are fixed. In addition, methods of improving the sensitivity of terminally fused biosensors are provided. The biosensors of the invention are useful for the detection and quantification of ligands in vivo and in culture. | 10-30-2014 |
| 20140323693 | Antibodies To Non-Functional P2X7 Receptor - The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between functional and non-functional p2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions. | 10-30-2014 |
| 20140323694 | MULTIPHASE POROUS FLOW REACTORS AND METHODS OF USING SAME - PFRs for running multiphasic processes are disclosed. The PFRs are single or multi-chamber devices having at least three types of regions (a liquid-contacting region, a gas-contacting region and a liquid-collection region), and a porous substrate providing fluid communication at least between the liquid-contacting and gas-contacting regions. Removal of liquid from the porous substrate, such as by collecting the liquid as it flows off the bottom of the porous substrate in the liquid-collection region or such as by evaporation of the liquid from the porous substrate in the evaporation region supports a continuous flow process. Methods of using the PFRs are also disclosed, for example methods of using the PFRs as photobioreactors for cultivating photosynthetic microorganisms, for producing fermentable sugars, for producing ethanol, for fermenting synthesis gas and producing single cell protein from natural gas. | 10-30-2014 |
| 20140343250 | RECOMBINANT BACTERIA RECOGNIZING PROTEIN AND USES THEREOF - The present invention relates to a recombinant protein comprising SEQ ID NO: 1 and a bacteria recognizing lectin. The present invention also relates to uses of the recombinant protein comprising detecting pathogens, removing endotoxins, determining the presence of an endotoxin or endotoxin-like material, and determining the presence of pathogen-associated molecular pattern (PAMP) comprising rhamnose-rhamnose (Rha-Rha), rhamnose-N-acetyl-mannosamine (Rha-ManNAc), N-acetyl-mannosamine-rhamnose (ManNAc-Rha), rhamnose-galatose (Rha-Gal), or galatose-rhamnose (Gal-Rha) in a sample, and use as a medicament, a disinfectant, a decontaminant, a surfactant or a diagnostic means. The present invention further relates to a method for prevention and/or treatment of conditions related to pathogen related infections in a patient in need thereof comprising: administering to said patient a pharmaceutically effective amount of composition comprising the recombinant protein, wherein the recombinant protein functions as an antagonist of PAMP comprising Rha-Rha, Rha-ManNAc, ManNAc-Rha, Rha-Gal, or Gal-Rha. | 11-20-2014 |
| 20140343251 | AGENTS AND METHODS FOR THE EXPRESSION AND SECRETION OF PEPTIDES AND PROTEINS - The present invention relates to a nucleic acid molecule for recombinant expression and secretion of a peptide or protein of interest comprising a hemolysin A and/or hemolysin C-derived nucleotide sequence, fragments thereof, homologs thereof, or the complements thereof, and a nucleotide sequence encoding the peptide or protein of interest. | 11-20-2014 |
| 20140350220 | NOVEL SURFACE EXPOSED HAEMOPHILUS INFLUENZAE PROTEIN (PROTEIN; pE) - The present invention relates to a surface exposed protein (protein E; pE), a virulence factor, which can be detected in | 11-27-2014 |
| 20140350221 | METHOD FOR DETERMINING INTRINSIC BINDING PARAMETERS OF AN ANALYTE TO A LIGAND, A METHOD FOR SELECTING AN ANALYTE FROM A GROUP OF ANALYTES, THE SELECTED LIGAND OR ANALYTE, AND SENSOR - The present invention relates to a method for determining intrinsic binding parameters, such as K | 11-27-2014 |
| 20140350222 | Microalgal Extraction - Disclosed herein is a process for extracting lipid containing products from microalgal biomass, the process comprising: (i) treating an aqueous mixture comprising microalgal biomass with microwave radiation and (ii) recovering lipid containing products from the treated microalgal biomass. | 11-27-2014 |
| 20140357842 | YERSINIA OUTER PROTEIN M (YOPM) IN THE TREATMENT OF PSORIASIS - The present invention relates to the use of Yersinia outer protein M (YopM)in the prevention and/or treatment of psoriasis by cutaneous, intradermalor subcutaneous administration. In particular, the present invention relates to the use of YopM in the treatment of plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, arthritis psoriasis. | 12-04-2014 |
| 20140364588 | PROTEIN ENRICHED MICROVESICLES AND METHODS OF MAKING AND USING THE SAME - Protein enriched micro-vesicles and methods of making and using the same are provided. Aspects of the methods include maintaining a cell having a membrane-associated protein comprising a first dimerization domain and a target protein having a second dimerization domain under conditions sufficient to produce a micro-vesicle from the cell, wherein the micro-vesicle includes the target protein. Also provided are cells, reagents and kits that find use in making the micro-vesicles, as well as methods of using the micro-vesicles, e.g., in research and therapeutic applications. | 12-11-2014 |
| 20140371425 | USE OF C1-INHIBITOR FOR THE TREATMENT OF SECONDARY EDEMA OF THE CENTRAL NERVOUS SYSTEM - The subject of the present invention is, in the most general aspect, the prevention and/or treatment of a secondary edema. In particular, the present invention relates to a C1-Inhibitor for use in a method of preventing the formation and/or reducing the size of a secondary edema of the central nervous system (CNS) in a subject wherein the subject has or has had at least one disorder selected from the group consisting of stroke, ischemic stroke, hemorrhagic stroke, perinatal stroke, traumatic brain injury and spinal cord injury. Preferably the secondary edema of the CNS is a secondary brain edema. Another subject of the present invention is the treatment of disorders associated with an increased permeability of the blood brain barrier or the blood spinal cord barrier. And a third subject is a plasma-derived C1-inhibitor for use in a method of preventing, reducing or treating brain ischemia-reperfusion injury. | 12-18-2014 |
| 20140378656 | SOLUBLE TCR MOLECULES AND METHODS OF USE - Disclosed are compositions and methods for detecting cells or tissue comprising a peptide antigen presented in the context of an MHC or HLA complex. The invention has a wide range of applications including providing a highly sensitive method for detecting cancer cells. | 12-25-2014 |
| 20140378657 | STREPTAVIDIN MUTEIN EXHIBITING REVERSIBLE BINDING FOR BIOTIN AND STREPTAVIDIN BINDING PEPTIDE TAGGED PROTEINS - The present invention relates to a new streptavidin muteins. This mutein is binds both streptavidin binding peptide tagged and biotin or biotinylated molecules, and does so in a reversible fashion. As such, it is stable enough to allow reuse, and producible with reasonable production yield via secretion in a soluble functional state without the requirement of refolding via the tedious and expensive denaturation and renaturation processes. | 12-25-2014 |
| 20140378658 | NEUROLOGICAL THERAPIES - Cytotoxic necrotising factor 1 (CNF1) treats dysfunctional astrocytes and is useful to treat conditions associated with astrogliosis and/or neuroinflammation. | 12-25-2014 |
| 20140378659 | OXIDIZED LDL INHIBITOR - The present invention provides an oxidized LDL inhibitor that is capable of (i) binding specifically to oxidized LDL, (ii) suppressing the physiological activity of oxidized LDL, and (iii) inhibiting the uptake of oxidized LDL into cells. The oxidized LDL inhibitor according to the present invention contains a Del-1 protein as an active ingredient. The Del-1 protein consists, for example, of the amino acid sequence of SEQ ID NO: 1. | 12-25-2014 |
| 20140378660 | MIRAC PROTEINS - This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures. | 12-25-2014 |
| 20150018521 | Endoplasmic Reticulum Localization Signals - The invention relates to cellular localization signals. In particular, the invention relates to endoplasmic reticulum localization signals in monomeric or multimeric form. The localization signals are utilized as research tools or are linked to therapeutics. Disclosed are methods of making and using polypeptides and modified polypeptides as signals to localize therapeutics, experimental compounds, peptides, proteins and/or other macromolecules to the endoplasmic reticulum of eukaryotic cells. The polypeptides of the invention optionally include linkage to reporters, epitopes and/or other experimental or therapeutic molecules. The invention also encompasses polynucleotides encoding the localization signals and vectors comprising these polynucleotides. | 01-15-2015 |
| 20150018522 | CATALYTIC DOMAINS OF BETA(1,4)-GALACTOSYLTRANSFERASE I HAVING ALTERED METAL ION SPECIFICITY - Disclosed are mutants of galactosyltransferases that can catalyze formation of oligosaccharides in the presence of magnesium; mutants of galactosyltransferases having altered donor and acceptor specificity which can catalyze formation of oligosaccharides in the presence of magnesium; methods and compositions that can be used to synthesize oligosaccharides; methods for increasing the immunogenicity of an antigen; and methods to stabilize platelets. | 01-15-2015 |
| 20150031855 | Methods for Enhancing Bacterial Cell Display of Proteins and Peptides - Methods of making and using bacterial display polypeptide libraries using circularly permuted OmpX (CPX) variants are disclosed. The invention further relates to methods for enhancing the display of proteins and peptides at the surface of bacteria by optimizing linkers and incorporating mutations at positions 165 and 166 of CPX. | 01-29-2015 |
| 20150031856 | Anaplastic Lymphoma Kinase (ALK) As An Oncogene Capable Of Transforming Normal Human Cells - The present invention provides compositions and methods for transforming primary mammalian cells using an oncogenic form of ALK wherein the transformed cells display features of that of a corresponding tumor cell isolated from a cancer subject. The invention also provides a method for immortalizing normal CD4+ T lymphocytes with a lymphoma-characteristic form of ALK such as NPM-ALK. | 01-29-2015 |
| 20150031857 | DENGUE SEROTYPE 2 ATTENUATED STRAIN - The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain. | 01-29-2015 |
| 20150031858 | Methods of Stimulating Protective Immunity Employing Dengue Viral Antigens - Compositions that include at least a portion of at least one pathogen-associated molecular pattern and at least a portion of at least one member selected from the group consisting of a Den1 viral envelope protein, a Den2 viral envelope protein, a Den3 viral envelope protein and a Den4 viral envelope protein are employed in methods to stimulate a protective immune response in a subject. | 01-29-2015 |
| 20150045537 | EXTRACELLULAR RELEASE OF LIPIDS BY PHOTOSYNTHETIC CELLS - The invention relates to methods for harvesting macromolecules such as lipids and proteins by culturing in growth medium a photo synthetic cyanobacteria that secretes vesicles into the growth medium, and separating the secreted vesicles from the cyanobacteria and/or from the growth medium. | 02-12-2015 |
| 20150051373 | CELLULOSE-/CHITIN-TYPE POLYMERIC LIGHT-EMITTING MATERIAL - The main object of the present invention is to provide a novel technique using a BAF. The invention that achieves the object provides the following: a chimeric protein comprising a luminescent domain and a cellulose- and/or chitin-binding domain, the luminescent domain comprising at least one luminescent protein selected from the group consisting of luciferases and fluorescent proteins. | 02-19-2015 |
| 20150051374 | FUSION PROTEINS OF SUPERFOLDER GREEN FLUORESCENT PROTEIN AND USE THEREOF - The present disclosure pertains to methods of producing recombinant peptides that contain between 10 and 200 amino acid residues using novel carrier proteins derived from superfolder green fluorescent protein and its mutants. | 02-19-2015 |
| 20150057434 | METHODS OF PURIFYING HYDROPHOBIN - The invention relates to a recovery and/or purification process of hydrophobins involving organic solvents and does not require separation techniques. In particular, the invention relates to a method for selective alcohol precipitation of hydrophobin II. | 02-26-2015 |
| 20150065684 | USE OF SOLUBLE FORMS OF CD83 AND NUCLEIC ACIDS ENCODING THEM FOR THE TREATMENT OR PREVENTION OF DISEASES - The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving dendritic cells, T cells and/or B cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies. | 03-05-2015 |
| 20150065685 | LASER-ACTUATED THERAPEUTIC NANOPARTICLES - The invention provides compositions and methods for laser actuated drug delivery. Compositions comprise serum albumin based particles conjugated with therapeutic agents which cab become bioavailable upon actuation of the particles by light, e.g. low power laser. | 03-05-2015 |
| 20150073125 | RECOMBINANT PROBIOTIC BACTERIA FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) AND IRRITABLE BOWEL SYNDROME (IBS) - The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof. | 03-12-2015 |
| 20150087809 | HLA-BINDING PEPTIDES, PRECURSORS THEREOF, DNA FRAGMENTS AND RECOMBINANT VECTORS THAT CODE FOR THOSE PEPTIDE SEQUENCES - An HLA-binding peptide binding to an HLA-A type molecule, said HLA-binding peptide comprising at least one type of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 183, and not less than 8 and not more than 11 amino acid residues is provided. Any of the amino acid sequence is predicted to have the binding property to a human HLA-A type molecule by a predicting program using an active learning experiment method as illustrated in FIG. | 03-26-2015 |
| 20150094450 | REPEBODY FOR NOVEL INTERLEUKIN-6 AND USE THEREOF - The present invention relates to an repebody capable of binding specifically to interleukin-6 (IL-6) to inhibit the biological activity of IL-6, a polynucleotide encoding the repebody, a vector comprising the polynucleotide, a recombinant microorganism having introduced therein the polynucleotide or the vector, a method of producing the repebody using the recombinant microorganism, a composition for preventing or treating cancer, which comprises the repebody, and a method for preventing or treating cancer, which comprises administering the composition for preventing or treating cancer, which comprises the repebody. The repebody of the present invention significantly reduces the activity of STAT3 and the concentration of interleukin-6, and thus can be widely used as an agent for preventing or treating IL-6-related diseases. | 04-02-2015 |
| 20150099859 | Deletion Mutants of Flagellin and Methods of Use - Compositions that include at least a portion of a flagellin and an antigen can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can be associated with particles and employed in the methods in relatively low doses to provide protective immunity to infection. | 04-09-2015 |
| 20150105536 | OBTAINING PRODUCTS FROM FEEDSTOCKS CONTAINING TOXIC ALGAE - Systems, methods, and other embodiments are described herein for obtaining products from heterogeneous feedstocks containing toxic algae. In one embodiment, a method includes collecting a heterogeneous feedstock. The heterogeneous feedstock is then processed. The embodiment further includes calculating a toxic value for the processed heterogeneous feedstock. It is then determined whether the toxic value of the processed heterogeneous feedstock satisfies a toxic threshold. In response to determining the toxic value does satisfy the toxic threshold, a product is extracted from the heterogeneous feedstock. | 04-16-2015 |
| 20150133635 | BACTERIAL TOXIN VACCINE - A bacterial toxin protein such as a Shiga toxin protein is efficiently produced using plant cells. The plant cells are transformed using a DNA construct containing DNA encoding a hybrid protein in which the bacterial toxin proteins such as the Shiga toxin proteins are tandemly linked through a peptide having the following characteristics (A) and (B) to produce the bacterial toxin protein in the plant cells: (A) a number of amino acids is 12 to 30; and (B) a content of proline is 20 to 35%. | 05-14-2015 |
| 20150141617 | PRODUCTION AND PURIFICATION OF ACTIVE EUKARYOTIC FORMYLGLYCINEGENERATING ENZYME (FGE) VARIANTS - The invention features compositions and methods for generation and uses of formylglycine generating enzyme (FGE) variants. | 05-21-2015 |
| 20150291671 | MODIFIED BIOTIN-BINDING PROTEIN - The present invention provides a modified biotin-binding protein comprising an amino acid sequence represented by SEQ ID NO: 2 or its modified sequence and having a biotin-binding activity and replacement selected from the group consisting of:
| 10-15-2015 |
| 20150307562 | ENGINEERED SECRETED PROTEINS AND METHODS - Nutritive proteins are provided herein. Also provided are various other embodiments including nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, vectors for expressing the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins. Nutritive proteins include engineered proteins, wherein the engineered proteins comprise a sequence of at least 20 amino acids that comprise an altered amino acid sequence compared to the amino acid sequence of a reference secreted protein and a ratio of essential amino acids to total amino acids present in the engineered protein higher than the ratio of essential amino acids to total amino acids present in the reference secreted protein. In some embodiments, the engineered protein comprises at least one essential amino acid residue substitution of a non-essential amino acid residue in the reference secreted protein. | 10-29-2015 |
| 20150307569 | HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A2* (HNRNP A2*) AND NUCLEIC ACID ENCODING THE SAME - An hnRNP A2* protein, including an amino acid sequence represented by SEQ ID NO. 1. The protein is a complete protein, a protein fragment, a protein analogue or a protein derivative. | 10-29-2015 |
| 20150315252 | PROTEIN ENRICHED MICROVESICLES AND METHODS OF MAKING AND USING THE SAME - The present invention relates to a microvesicle comprising: (i) a membrane-associated protein comprising at least one first dimerization domain, (ii) a carrier protein comprising at least one second dimerization domain, and (iii) a solute that binds to the carrier protein, wherein the solute is selected from the group of: DNA, RNA, protein, carbohydrate, ribosomes, mitochondria, and small molecules. Also provided are cells, reagents and kits that find use in making the microvesicles, as well as methods of using the microvesicles, e.g., in research and therapeutic applications | 11-05-2015 |
| 20150329598 | STABILIZED HEPATITIS B CORE POLYPEPTIDES - Genetically modified HBc polypeptides are provided. | 11-19-2015 |
| 20150329605 | METHOD FOR STABILIZING PROTEIN - An excellent protein stabilizer is provided, which has the following effects: (1) low probability with contamination of pathogens, (2) the effect of stabilization on photoproteins, and (3) minimization of loss of activity under lyophilizing conditions. A peptide from fish is used as the active ingredient for the protein stabilizer. | 11-19-2015 |
| 20150329606 | METHOD FOR PREPARING C1Q RECOMBINANT PROTEIN - The present invention relates to a method for recombinant production of a C1q protein or a variant of the C1q protein, in which the protein is recovered from an in vitro culture of cells expressing a C1qA subunit or a variant of the C1qA subunit, a C1qB subunit or a variant of the C1qB subunit, and a C1qC subunit or a variant of the C1qC subunit, in which at least one of the subunits or subunit variants also has at the N-terminus or C-terminus a sequence of amino acids of at least six residues, at least 40% of which are glutamic acid and/or aspartic acid residues. | 11-19-2015 |
| 20150329609 | CHIMERIC DYSTROPHIN PROTEINS TO TREAT DYSTROPHINOPATHIES - A chimeric protein that is a fusion construct of a series of functional domains is used to deliver a therapeutic agent to a human subject suffering from disease. In some embodiments, the chimeric protein includes a therapeutic region and a transportation region. The transportation region allows the chimeric protein to be moved across a cellular membrane of an affected cell within the subject. The therapeutic region can be effective in the treatment of, for example, muscular dystrophy, diastrophic dysplasia, malignant melanoma, porphyria, alpha-1 antitrypsin deficiency, Aicardi-Goutieres syndrome, cystic fibrosis, progeria, Marfan syndrome, tuberous sclerosis, adrenoleukodystrophy, and the like. | 11-19-2015 |
| 20150376250 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF OXYGEN - H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O | 12-31-2015 |
| 20160002305 | ARTIFICIAL BIOPARTICLE AND METHOD OF MANUFACTURING THE SAME - According to an artificial bioparticle characterized in that a leucine zipper is integrated in each N terminal of an MVP constituting a waist of a vault and a method of manufacturing an artificial bioparticle in which a leucine zipper gene is integrated and expressed in a side to be an N terminal of an MVP gene, a novel artificial bioparticle including a vault of which large internal space can effectively be made use of, which can be used as a nanocapsule applicable to a drug delivery system (DDS), and a method of manufacturing the same are provided. | 01-07-2016 |
| 20160002307 | LMNA GENE AND ITS INVOLVEMENT IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND ARTERIOSCLEROSIS - Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is 50 amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), methods of treating such conditions, methods of selecting treatments, methods of screening for compounds that influence Lamin A activity, and methods of influencing the expression of LMNA or LMNA variants are also described. Oligonucleotides and other compounds for use in examples of the described methods are also provided, as are protein-specific binding agents, such as antibodies, that bind specifically to at least one epitope of a Lamin A variant protein preferentially compared to wildtype Lamin A, and methods of using such antibodies in diagnosis, treatment, and screening. Also provided are kits for carrying out the methods described herein. | 01-07-2016 |
| 20160022801 | RODENT HEPADNAVIRUS CORES WITH REDUCED CARRIER-SPECIFIC ANTIGENICITY - The present disclosure generally relates to hepadnavirus core antigens in which one or more endogenous b cell epitopes have been effectively removed. More specifically, the present disclosure relates to rodent hepadnavirus cores modified to diminish the antibody response to the core so as to enhance the antibody response to heterologous polypeptides included therein. | 01-28-2016 |
| 20160031966 | MUTANT PROTEINS AND METHODS FOR THEIR PRODUCTION - The present invention relates to mutant transmembrane proteins which have increased conformational stability when compared to their parent protein, methods of selection and production. In particular the invention relates to mutant transmembrane proteins which are mutated in or in the proximity of the transmembrane alpha helices or in a kinked region or in an alpha-helix adjacent to a kink. The mutant transmembrane proteins have use in crystallisation studies and also in screening to identify compounds for use in drug discovery and therapy. | 02-04-2016 |
| 20160052991 | MUTANT G-PROTEIN COUPLED RECEPTORS AND METHODS FOR SELECTING THEM - The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same. | 02-25-2016 |
| 20160058835 | USE OF TAENIA SOLIUM RECOMBINANT CALRETICULIN FOR INDUCING INTERLEUKIN-10 EXPRESSION - The present invention is related to the use of a recombinant protein to induce interleukin 10 expression, wherein the protein is | 03-03-2016 |
| 20160060310 | Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Hepatocellular Carcinoma Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Hepatocellular Carcinoma Compositions Comprising the Same - Protein transduction exploits the ability of some cell-penetrating peptide (CPP) sequences to enhance the uptake of proteins and other macromolecules by mammalian cells. Previously developed hydrophobic CPPs, named membrane translocating sequence (MTS), membrane translocating motif (MTM) and macromolecule transduction domain (MTD), are able to deliver biologically active proteins into a variety of cells and tissues. Various cargo proteins fused to these CPPs have been used to test the functional and/or therapeutic efficacy of protein transduction. For example, recombinant proteins consisting of suppressor of cytokine signaling 3 protein (CP-SOCS3) fused to the fibroblast growth factor (FGF) 4-derived MTM were developed to inhibit inflammation and apoptosis. However, CP-SOCS3 fusion proteins expressed in bacteria were hard to purify in soluble form. To address these critical limitations, CPP sequences called advanced MTDs (aMTD) have been developed in this art. This is accomplished by (i) analyzing previous developed hydrophobic CPP sequences to identify specific critical factors (CFs) that affect intracellular delivery potential and (ii) constructing artificial aMTD sequences satisfied for each critical factor. In addition, solubilization domains (SDs) have been incorporated into the aMTD-fused SOCS3 recombinant proteins to enhance solubility with corresponding increases in protein yield and cell-/tissue-permeability. These recombinant SOCS3 proteins fused to aMTD/SD having much higher solubility/yield and cell-/tissue-permeability have been named as improved cell-permeable SOCS3 (iCP-SOCS3) proteins. Previously developed CP-SOCS3 proteins fused to MTM were only tested or used as anti-inflammatory agents to treat acute liver injury. In the present art, iCP-SOCS3 proteins have been tested for use as anti-cancer agents in the treatment of hepatocellular carcinoma. Since SOCS3 is frequently deleted in and loss of SOCS3 in hepatocytes promotes resistance to apoptosis and proliferation, we reasoned that iCP-SOCS3 could be used as a protein-based intracellular replacement therapy for the treatment of hepatocellular carcinoma. The results support this reasoning: treatment of hepatocellular carcinoma cells with iCP-SOCS3 results in reduced cancer cell viability, enhanced apoptosis and loss of cell migration/invasion potential. Furthermore, iCP-SOCS3 inhibits the growth of hepatocellular carcinoma in a subcutaneous xenografts model. In the present invention with iCP-SOCS3 fused to an empirically determined combination of newly developed aMTD and customized SD, macromolecule intracellular transduction technology (MITT) enabled by the advanced MTD may provide novel protein therapy against hepatocellular carcinoma. | 03-03-2016 |
| 20160089448 | POLYMERIC PRODRUG WITH A SELF-IMMOLATIVE LINKER - A cascade carrier linked prodrug is described comprising a biologically active moiety and a masking group having at least one nucleophile and being distinct from the carrier. | 03-31-2016 |
| 20160090400 | ANTIBODY LIKE PROTEIN - A general method and recombinant nucleic acid sequences, by means which the method selects a recombinant protein containing an FHA domain for binding a target molecule from a library proteins with a high-throughput method of creating protein variations within the FHA domain in non-conserved or non-structural sequences of the FHA scaffold, and the library may also be in the form of a phagemid or phage library wherein the ALP nucleic acid sequence is inserted into a vector capable of allowing the vector and expressed ALP protein from being virally packaged, and the recombinant nucleic acid sequences which are randomly mutated at varying non-conserved or non-structural FHA domain sequences. | 03-31-2016 |
| 20160090404 | MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS THEREOF AND APPLICATIONS - The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from | 03-31-2016 |
| 20160096868 | Mussel-inspired bioactive surface coating composition generating silica nanoparticles - The present invention relates to a fusion protein comprising a mussel adhesive protein and a silica-binding peptide linked to the mussel adhesive protein, a silica nanoparticle a silica connected to the fusion protein, a fusion protein-silica nanoparticle complex comprising the silica nanoparticle having bioactivity and adhesiveness for cell proliferation and accelerating the differentiation, a surface coating composition including the complex, its use, and a method of coating a surface using the surface coating composition. | 04-07-2016 |
| 20160096872 | METHODS FOR PRODUCING PEPTIDES USING ENGINEERED INTEINS - The present invention provides a method for producing peptides by recombinant means. The peptides are expressed as part of a fusion protein comprising the target peptide and an engineered intein. The invention also provides the engineered inteins, fusion proteins comprising these, and DNA constructs coding for these fusion proteins. Upon thiol-induced cleavage of the fusion protein the carboxy-terminal a-thioester of the target peptide is obtained. The carboxy-terminal ct-thioester can in principle react with any nucleophile and the strategy therefore allows a wider range of carboxy-terminal modifications such as chemical ligation, bioconjugation, or amidation. The engineered inteins of the present invention are minimized in size and has a cysteine mutation in the position corresponding by alignment to position 3 of Mxe GyrA intein (SEQ ID NO:1) leading to increased expression levels of the fusion protein and higher yields of the isolated target peptide, thus making the method of the invention suitable for production scale. | 04-07-2016 |
| 20160115503 | PROCESS AND METHOD FOR IMPROVING FERMENTATION BY THE ADDITION OF HYDROTHERMALLY TREATED STILLAGE - A method of improving fermentation by increasing the bioavailability of components in stillage, using all or a portion of the hydrothermally treated stillage as a component of a media, and using the media for a process such as fermentation or biomass production. The metabolites and biomass recovered from the method above. Media including hydrothermally treating stillage obtained by heating the stillage to a temperature of 190° F. to 300° F. A method of improving fermentation by removing solids in stillage, hydrothermally treating the stillage by heating the stillage to a temperature of 190° F. to 300° F., using all or a portion of the stillage as a component of a media, and using the media for a process chosen from the group consisting of fermentation and biomass production. | 04-28-2016 |
| 20160130310 | NOVEL RHTB PROTEIN VARIANTS AND THE METHOD OF PRODUCING O-PHOSPHOSERINE USING THE SAME - The present invention relates to an RhtB (homoserine/homoserine lactone export transporter) protein variant having an enhanced ability to export O-phosphoserine (OPS) that is a precursor of L-cysteine, a polynucleotide encoding the protein, a vector comprising the polynucleotide, an OPS-producing microorganism comprising the protein variant, a method of producing O-phosphoserine using the microorganism, and a method for preparing cysteine or its derivatives, which comprises reacting O-phosphoserine, produced by the method above, with a sulfide in the presence of O-phosphoserine sulfhydrylase (OPSS) or a microorganism that expresses OPSS. | 05-12-2016 |
| 20160137703 | MSP Nanopores and Related Methods - Provided herein are | 05-19-2016 |
| 20160145317 | TRAIL Mutant Membrane-Penetrating Peptide-alike, Preparation Method and Application - The invention mainly relates to the field of genetic engineering drugs, in particular to a mutant cDNA sequence obtained by mutating valine at position | 05-26-2016 |
| 20160152685 | SMALL MOLECULE-DEPENDENT INTEINS AND USES THEREOF | 06-02-2016 |
| 20160159879 | REGULATION OF SODIUM CHANNELS BY PLUNC PROTEINS - The present invention relates to the ability of PLUNC proteins, such as SPLUNC1 and SPLUNC2, to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of PLUNC proteins to sodium channels. | 06-09-2016 |
| 20160178635 | Human cellular models with biosensors | 06-23-2016 |
| 20160185825 | ENGINEERED OUTER DOMAIN (EOD) OF HIV GP120 AND MUTANTS THEREOF - The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings. | 06-30-2016 |
| 20160185828 | Genetic Reprogramming of Bacterial Biofilms - Described herein are methods and compositions relating to engineered curii fibers, e.g. CsgA polypeptide. In some embodiments, the methods and compositions described herein relate to functionalized biofilms. In one aspect, described herein is an engineered CsgA polypeptide, comprising a CsgA polypeptide with a C-terminal display tag flanking the CsgA polypeptide; wherein the display tag comprises an activity polypeptide and a linker sequence. In some embodiments, the display tag and/or the activity polypeptide comprises a polypeptide selected from the group consisting of metal binding domain (MBD); Spy Tag; graphene binding (GBP); carbon nanotube binding (CBP); gold binding (A3); CT43; FLAG; Z8; E14; QBP1; CLP12; and AFP8. | 06-30-2016 |
| 20160200793 | FLT4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY | 07-14-2016 |
| 20160250316 | IMMUNOGENIC POLYPEPTIDES COMPRISING A SCAFFOLD POLYPEPTIDE AND A L2 POLYPEPTIDE OR A FRAGMENT THEREOF | 09-01-2016 |
| 20160250341 | DESIGNED REPEAT PROTEINS BINDING TO SERUM ALBUMIN | 09-01-2016 |
| 20160252530 | AGENT FOR PREVENTING OR TREATING SPINOCEREBELLAR ATAXIA | 09-01-2016 |
| 20160376327 | Fusobacterium polypeptides and methods of use - The present invention provides isolated polypeptides isolatable from a | 12-29-2016 |
| 20160376348 | METHODS AND COMPOSITIONS RELATED TO SOLUBLE MONOCLONAL VARIABLE LYMPHOCYTE RECEPTORS OF DEFINED ANTIGEN SPECIFICITY - Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed. | 12-29-2016 |
| 20190144512 | FUSION PROTEINS OF SUPERFOLDER GREEN FLUORESCENT PROTEIN AND USE THEREOF | 05-16-2019 |
| 20190147972 | BIOMOLECULE DESIGN MODEL AND USES THEREOF | 05-16-2019 |
| 20220133867 | USE OF ELAFIN FOR DISORDERS ASSOCIATED WITH ELASTASE INDEPENDENT INCREASE IN TROPONIN - The present invention relates to the use of elafin for the treatment and/or prevention of diseases or disorders associated with an increase in troponin levels, which are non elastase dependent. The present invention in a preferred embodiment relates to a method and composition, using elafin, for protecting the heart muscle or other muscles from damage induced by abnormal blood flow and/or inflammation, which may result from, for example, a heart infarction. The present invention additionally or concomitantly relates to the use of elafin for the treatment and/or prevention of disorders or diseases which are associated with a rise in the level of troponin I and/or T. | 05-05-2022 |
